bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

Combinatorial optimization of mRNA structure, stability, and translation for
RNA-based therapeutics
Kathrin Leppek1*, Gun Woo Byeon1*, Wipapat Kladwang2*, Hannah K. Wayment-Steele3*, Craig
H. Kerr1*, Adele F. Xu1**, Do Soon Kim2**, Ved V. Topkar4, Christian Choe5, Daphna Rothschild1,
Gerald C. Tiu1, Roger Wellington-Oguri6, Kotaro Fujii1, Eesha Sharma2, Andrew M. Watkins2,
John J. Nicol6, Jonathan Romano6,7, Bojan Tunguz2, Eterna Participants6, Maria Barna1‚Ä°, Rhiju
Das2‚Ä°
1

Department of Genetics, Stanford University, Stanford, California 94305, USA

2

Department of Biochemistry, Stanford University, California 94305, USA

3 Department of Chemistry, Stanford University, Stanford, California 94305, USA
4 Program in Biophysics, Stanford University, Stanford, California 94305, USA
5 Department of Bioengineering, Stanford University, Stanford, California 94305, USA
6

Eterna Massive Open Laboratory

7

Department of Computer Science and Engineering, State University of New York at Buffalo,

Buffalo, New York, 14260, USA
* these authors contributed equally
** these authors contributed equally
‚Ä° co-corresponding authors
Contact: Maria Barna: mbarna@stanford.edu; Rhiju Das: rhiju@stanford.edu

Running title: Combinatorial mRNA optimization
Key words: RNA structure, mRNA translation, RNA stability, polysome profiling, vaccine, CDS
sequence variants, Eterna, in-line RNA structure probing

1

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

SUMMARY
Therapeutic mRNAs and vaccines are being developed for a broad range of human diseases,
including COVID-19. However, their optimization is hindered by mRNA instability and inefficient
protein expression. Here, we describe design principles that overcome these barriers. We
develop a new RNA sequencing-based platform called PERSIST-seq to systematically delineate
in-cell mRNA stability, ribosome load, as well as in-solution stability of a library of diverse
mRNAs. We find that, surprisingly, in-cell stability is a greater driver of protein output than high
ribosome load. We further introduce a method called In-line-seq, applied to thousands of
diverse RNAs, that reveals sequence and structure-based rules for mitigating hydrolytic
degradation. Our findings show that ‚Äúsuperfolder‚Äù mRNAs can be designed to improve both
stability and expression that are further enhanced through pseudouridine nucleoside
modification. Together, our study demonstrates simultaneous improvement of mRNA stability
and protein expression and provides a computational-experimental platform for the
enhancement of mRNA medicines.

INTRODUCTION
Messenger RNA (mRNA) therapeutics hold the potential to transform modern medicine by
providing a gene therapy platform with the capacity for rapid development and wide-scale
deployment. Compared to recombinant proteins, manufacturing of mRNA is faster, more
cost-effective, and more flexible because mRNA can be easily produced by in vitro transcription.
Over the past decade, technological discoveries in the areas of mRNA modifications and
delivery systems have rapidly advanced basic and clinical research in mRNA vaccines1‚Äì3.
However, technical obstacles facing mRNA therapeutics are also apparent. For example, mRNA
vaccines still suffer from decreased efficacy due to poor RNA stability in solution and in vivo and
to limited expression of the payload mRNA; these are all pivotal issues that need to be carefully
optimized for preclinical and clinical applications3‚Äì6.
The development of mRNAs redesigned for increased stability and expression could
maximize the impact of producing, delivering, and administering therapeutic mRNAs. However,
achieving such designs is hindered by a poor understanding of how the sequence and structure
of an mRNA influence its expression and stability, both in solution and in cells. For example, it
has typically been assumed that mRNAs with more stable secondary structure might have
increased in-solution stability but would have lower in-cell protein output due to the increased
difficulty of the cellular translation machinery to process through RNA structure7, but this has not
2

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

been tested and some recent results suggest that there might not be such a tradeoff8,9. Our poor
understanding of these design rules is due in part to the historical difficulty of rapidly
synthesizing full-length mRNAs with different untranslated regions (UTRs) and coding
sequences (CDSs) which would enable high-throughput experimental approaches comparing
their stability and expression.
Here, we overcome these technical hurdles and characterize hundreds of full-length
reporter constructs that encode mRNA sequences with a wide variety of UTRs and CDSs. We
present a massively parallel reporter assay termed Pooled Evaluation of mRNA in-solution
Stability, and In-cell Stability and Translation RNA-seq (PERSIST-seq), which enables
systematic determination of the effects of UTR, codon choice and RNA structure on mRNA
translation rates in human cells and on mRNA stability, both in cells and in solution. This
represents the first large-scale screen of mRNA redesigned across its entire length. We further
leverage the unique ability of the Eterna10 community, an online citizen science platform that
enables participants to collectively solve RNA design puzzles, to devise solutions with high
diversity in sequence and predicted structure. We integrate our datasets to develop a model that
accurately predicts protein output for a given mRNA based on its ribosome load and in-cell
stability. This model enables identification of optimal mRNA designs without the need to
individually test all mRNAs for protein output. With the further aim of understanding the impact
of mRNA structure on in-solution stability, we developed a high-throughput method termed
In-line-seq to measure RNA degradation patterns arising from intrinsic in-line hydrolysis.
Nucleotide-resolution data on thousands of small, structured model RNAs from the Eterna
platform revealed novel design rules for reducing solution hydrolysis and enabled development
of a regression model termed DegScore that enables in silico RNA sequence optimization for
enhanced in-solution stability. Finally, we compare the effect of nucleoside modifications on
mRNA performance, including unexpected results of pseudouridine (œà) and its derivatives on
in-solution stability. Ultimately, our findings culminate in the fully automated design of mRNAs
containing 5‚Äô and 3‚Äô UTR elements and structure-optimized CDS regions that simultaneously
confer high stability in solution and high protein expression in cells. Together, the combination of
optimized UTRs for expression, DegScore-optimized CDS structure, and œà modification
provides a general technology that can be applied to stabilize and increase protein expression
of candidate mRNA therapeutics. We envision that these design rules and our combinatorial
mRNA optimization platform will be widely applicable to rapidly engineer future mRNA
therapeutics that simultaneously optimize stability and potency.

3

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

RESULTS
A combinatorial library for systematic discovery of mRNA design rules
In search of design rules for stable and high-expressing mRNAs, we aimed to characterize a
large number of mRNA sequence designs with extensive variations in 5‚Äô UTR, CDS, and 3‚Äô UTR
regions. We took advantage of recent accelerations in commercial gene synthesis and
developed the massively parallel assay PERSIST-seq (Fig. 1A, Fig. S1). In this method, mRNA
variants can be assayed in parallel for translation efficiency in cells, for stability in cells, and for
stability in solution. Full-length in vitro transcription (IVT) DNA templates were obtained through
commercial gene synthesis services (Twist, Genscript, Codex). Each template incorporated
three additional features: (1) a shared T7 promoter sequence for performing IVT, (2) barcodes
in the 3‚Äô UTR to enable multiplexing via inexpensive, short-read sequencing, and (3) a constant
region at the 3‚Äô end that enabled pooled PCR and reverse transcription (RT) reactions (Fig. S1).
This design allowed one-pot amplification and analysis of the library using common flanking
sequences. The library was in vitro transcribed, modified (3‚Äô polyA-tailing and 5‚Äô m7G-capping),
transfected into cells and quantified by barcode sequencing in a pool (Fig. 1B), enabling
straightforward measurements of translation by polysome profiling or of mRNA degradation over
time in cells or in solution.
Our mRNA library contained 233 different mRNA sequences in total (Table S1). 112 of
these mRNAs contained varied 5‚Äô and/or 3‚Äô UTRs (Fig. 1A). While there have been many efforts
to optimize protein expression by attaching UTRs found in highly translated or stable
mRNAs11‚Äì13, previous work tested and characterized only a handful of candidates at a time,
either with a focus on individual functional UTR elements14 or on screening randomized short
UTRs15‚Äì18. We decided to harness full-length naturally occuring UTRs to optimize mRNA
expression. Thus, we included a wide variety of 5‚Äô and 3‚Äô UTR sequences from cellular and viral
genomes in our systematic analysis due to their potential to enhance or fine-tune mRNA
translation or stability.
As examples of cellular sequences, we included short 5‚Äô UTRs of cellular mRNAs
corresponding to highly abundant proteins that have a high translation rate such as ribosomal
proteins (RPs) (RPS25, RPL31, RPL38), or structural components such as tubulin beta-2B
chain (Tubb2b) and actin (ActB), as well as human collagen, type I, alpha 2 (hCOL1A2)19. We
further included regulatory 5‚Äô UTR elements such as the 5‚Äô terminal oligopyrimidine (TOP) motif
from RPL18, which promotes translational activation downstream of mTOR20,21, as well as the
Hoxa9 P4 RNA stem-loop which functions as a translation enhancer22. 5‚Äô UTRs previously
identified in translation efficiency screens such as complement factor 3 (C3), cytochrome P450
4

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

2E1 (CYP2E1), and Apolipoprotein A-II (APOA2)12, as well as plant rubisco components
(RBCS3B, RBCS1A)23, were also included. For 3‚Äô UTR regions (total 22; size range 60-597 nt),
we employed known stabilizing RNA structures such as the MALAT1 non-coding RNA
3‚Äô-stem-loop structure that resembles an expression and nuclear retention element (ENE) and
engages a downstream A-rich tract in a triple helix structure24,25, as well as known expression
enhancing 3‚Äô UTRs such as those from human hemoglobin subunit alpha 1 (HBA1)26 and
cytochrome B-245 alpha chain (CYBA)27,28.
Viruses have evolved a suite of compact regulatory elements for hijacking the host
translation machinery to effectively promote translation and stability of their own mRNAs. For
example, internal ribosome entry sites (IRESs) can recruit ribosomes to initiate translation
without the need for the full repertoire of eukaryotic initiation factors, whereas other elements in
the 5‚Äô and 3‚Äô UTRs of viruses encode structures that facilitate long-range RNA-RNA interactions
to enhance protein expression or mRNA stability. Therefore, several UTRs originating from viral
genomes were included: the 5‚Äô and 3‚Äô UTR elements of the SARS-CoV-2 RNA genome29,30,
along with variants described below; the dengue virus (DEN2) 5‚Äô and 3‚Äô UTRs, which are
thought to enhance viral protein expression31,32; 5‚Äô and 3‚Äô UTR elements from various
tombusviruses (e.g., turnip crinkle virus (TCV)) which encode 3‚Äô cap-independent translational
enhancer RNA structures that recruit the translational machinery33,34; tobacco mosaic virus35
(TMV) and tobacco etch virus36 (TEV) 5‚Äô leader sequences; a poxvirus poly(A) leader sequence
that is proposed to facilitate translation37; and the 3‚Äô UTRs of Sindbis virus (SINV) and the rabies
virus glycoprotein, which increase viral RNA stability through recruitment of host proteins38‚Äì40.
As our main reference, we chose the 5‚Äô and 3‚Äô UTRs from human hemoglobin subunit
beta (hHBB), which is one of the most efficiently expressed mammalian mRNAs and is
commonly used in investigations of mRNA translation and stability41,42. Non-hHBB UTRs are
referred to here as ‚ÄúUTR variants.‚Äù To test these UTR variants, all reporter mRNAs encode the
Nanoluc luciferase (Nluc) open reading frame (ORF) as its CDS region43,44. We decided to use
Nluc because its short ORF of 621 nt allowed for synthesis and pooled amplification of
full-length DNA templates with UTRs of up to 600 nt attached at each end. Employing Nluc
further enabled precise quantitative readout for comparing translation efficiencies in follow-up
experiments on individual mRNAs through ratiometric measurements including a firefly
luciferase (Fluc) mRNA spike-in control in transfection experiments integrated with luciferase
luminescence assays22. Additional mRNAs encoding for enhanced green fluorescent protein
(eGFP) and a shorter candidate multi-epitope vaccine (MEV)7 were included as controls in some
experiments, further discussed below.

5

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

To test the impact of CDS sequence and predicted CDS structure on mRNA stability and
translation, we sought to maximize the diversity of CDS sequences and structures for model
protein targets. Consequently, we asked participants from the Eterna massive open laboratory10
to design CDSs encoding a variety of model mRNAs, without specific optimization metrics, in a
series of challenges (Fig. 1A). These puzzles included design challenges for eGFP, MEV, and
Nluc (‚ÄòOpenVaccine: Design of eGFP and epitope mRNA molecules‚Äô and ‚ÄòOpenVaccine:
Lightning Round Design + Vote of Nanoluciferase‚Äô). Later rounds of design challenges included
degradation-specific metrics (AUP and DegScore, discussed later) within the game interface to
guide optimization. We also included CDSs using several algorithmic approaches. First, we
included sequences designed using commercially available algorithms to optimize codon
adaptation index (CAI)45. Second, we designed sequences using a ‚ÄúGC-rich‚Äù approach, in which
each codon is stochastically sampled from codons highest in GC content, based on a strategy
developed by CureVac researchers9. Third, we included CDSs designed using the LinearDesign
algorithm46, which returns a deterministic minimal free energy solution that is weighted by codon
optimality. Finally, we used the Ribotree Monte Carlo tree search method to optimize AUP for
eGFP and to compare to eGFP designs developed by Moderna researchers7,8. These design
methods yielded a total of 121 CDS variants in the library (Fig. 1A, Table S1). To ensure useful
cross comparison, hHBB UTRs were used for each of these CDS variants. Together, all
candidates from these diverse sources of UTR and CDS sequences were combined into a
single library of 233 mRNA constructs.
High dynamic range of translation driven by UTRs
To assess translation efficiencies relevant for potency of mRNA therapeutics, PERSIST-seq
transfects mRNA pools into human cells (here HEK293T). Cell lysate then undergoes sucrose
gradient fractionation, which separates mRNAs into actively translating and non-translating
fractions that are analyzed by RT-PCR of barcode regions and Illumina sequencing. Actively
translating mRNAs have a higher number of ribosomes associated with them and are found in
polysomal fractions whereas non-translating or poorly translating mRNAs are present in the free
mRNA fraction or are associated with 40S ribosomal subunits (Fig. 1C). After initial studies
confirming differences in polysome loading of a highly translated endogenous mRNA, human
ActB, with that of a transfected control mRNA that has scrambled short UTR sequences43 (Fig.
S1D), we carried out PERSIST-seq to examine the polysome profiles of diverse constructs in
the 233x-mRNA library. We observed a wide variation in mRNA distribution across the fractions
(here expressed as ribosome load, defined as the weighted sum of mRNA proportions multiplied

6

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

by the ribosome number in a fraction) (equation in Fig. 1D). The largest variation in ribosome
load was observed for the 5‚Äô UTR variants group (Fig. 1D). These data suggested strong
potential for using different 5‚Äô UTRs to tune translational efficiency of target mRNAs ‚Äì more than
for any other region (3‚Äô UTR or CDS).
We categorized the origins of UTR sequences described above as ‚Äúcellular‚Äù, ‚Äúviral‚Äù, and
‚Äúchimera‚Äù (modular UTR combinations). Overall, the mRNA designs with highest ribosome load
were observed across 5‚Äô UTRs of cellular as well as viral origins (Fig. 1E, Table S1). These 5‚Äô
UTRs included: mouse COL1A2, Hoxa9 P4, Rpl18a TOP, plant RBCS1A; the poxvirus poly(A)
leader sequence fused to a scrambled 5‚Äô UTR sequence and also the 5‚Äô UTRs of plant viruses
TEV and TMV. The dengue virus 5‚Äô and 3‚Äô UTRs both individually increase ribosome loading,
and combining them into one mRNA resulted in an additive effect (Fig. 1E, Table S1). All of
these sequences had a higher ribosome load (1.7-2.3) than the hHBB 5‚Äô UTR (1.57), thereby
identifying potential UTR design strategies to boost mRNA translational efficiency. Moreover, the
chimeric fusion of the hHBB 5‚Äô UTR with elements such as the TEV or 5‚Äô TOP sequence in the
same 5‚Äô UTR increased polysome loading. Overall, our polysome screen successfully identified
a wide range of 5‚Äô UTR sequences that can be deployed to successfully promote translation
within cells. Most surprising, in contrast to previous reports47‚Äì49, we found 5‚Äô UTRs that are
highly structured, such as the dengue virus (DEN2), can support efficient translation.
We next asked if the highly structured 5‚Äô UTRs used in our screen could be augmented
to further improve ribosome loading. To this end, we performed a detailed mutagenesis analysis
of the structured 5‚Äô UTR30,50‚Äì52 from SARS-CoV-2 genomic RNA29,30 as a paradigmatic example
(Fig. 1F). We first observed that mutation of the uORF in the 5‚Äô UTR (AUG mutated to UUG;
CoV2-UUG) resulted in higher ribosome load than the wildtype 5‚Äô UTR (Fig. 1F-G). Then, to
systematically determine the impact of each stem-loop on ribosome load, we introduced partial
and full truncations of stem-loops (SL) 1-5 (SL1-5) into CoV-2-UUG. (Fig. 1F, Table S2).
Additionally, we included larger truncations of combined deletions of adjacent stem-loops and
introduced the Hoxa9 P4 stem-loop, a 35 nt element that recruits 40S ribosomal subunits to
enhance translation22, in lieu of the uORF (Fig. 1F-G, Table S2). Intriguingly, polysome profiling
of the 5‚Äô UTR SL mutant constructs revealed a wide range of overall improved ribosome load
(Fig. 1G). Deleting the full 5‚Äô half (dSL1-3) or the 3‚Äô half (dSL4-5) of the 5‚Äô UTR overall
increased ribosome load. In particular, deletion of SL1 from the SARS-CoV-2 5‚Äô UTR increased
ribosome load from 1.23 (CoV-2) to 1.5 (CoV-2-UUG-dSL-1) which almost reaches the level of
ribosome load of hHBB (1.57) (Fig. 1G). These results on the SARS-CoV-2 5‚Äô UTR indicate that

7

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

ribosome load can be fine-tuned through the modulation of distinct elements in structured viral
5‚Äô UTRs, and that these effects can be read out through PERSIST-seq.
Inspired by these PERSIST-seq results, we sought to further understand how sequence
and structure variation of 5‚Äô UTRs might modulate translation efficiency through an unbiased
selection from a complex sequence library (Fig. S2). We selected for highly translating
transcripts by transfecting an mRNA reporter library containing randomized 5‚Äô UTR sequences
and harvesting mRNAs associated with heavy polysomes (Fig. S2A). We further enriched these
libraries for highly translating transcripts over five total rounds of selection and re-transfection of
the heavily ribosome-loaded mRNAs from two independent starting pools (Fig. S2A-C). We
then functionally assessed the protein output of the top 15 sequences by normalized read
abundance (Fig. S2D). We found the most impactful effects of sequence k-mers at the 5‚Äô and 3‚Äô
end of the randomized 5‚Äô UTR stretch (Fig. S2E, Table S3). These effects included significant
depletion of 5‚Äô UTRs that contain out-of-frame AUG start codons relative to the main ORF and
enrichments of short stem-loop motifs promoting translation (Fig. S2F). Interestingly,
one-by-one tests of the 5‚Äô UTRs selected to have high ribosome load gave lower total protein
output than the starting sequence (see Supplemental Text); this observation foreshadowed a
tradeoff between ribosome load and mRNA stability that we dissect in greater detail below.
Beyond effects of varying sequence and structure of UTRs, we were interested in
delineating how variations of the CDS might impact mRNA translation3,8,45. As noted above, we
observed less variance in ribosome loading among CDS variants than for UTR variants (Fig.
1D-E). The only clear effects on ribosome load were that MEV-encoding CDS variants displayed
less ribosome load than Nluc- or eGFP-encoding CDS variants, as expected from their shorter
ORFs. For Nluc-encoding mRNAs, CDS variants were similar in ribosome load or showed a
shift towards being less loaded with ribosomes. The ribosome load of CDS variants had no
obvious correlation with the codon adaptation index (CAI), GC content, minimum free energy
(MFE), addition of signal peptides, or nonsynonymous mutations (Table S1). We did note that
mRNAs designed to have highly structured CDSs by the LinearDesign algorithm exhibited
polysome fraction profiles dominated by 80S monosomes (Fig. 1E), further discussed below.
Taken together with our results above, these PERSIST-seq measurements indicate that
structured CDS regions and a wide variety of 5‚Äô UTR elements from cellular and viral origins can
sustain or even improve in-cell translation efficiency compared to reference mRNA sequences.

8

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

In-cell mRNA stability is a major predictor of total protein output
The total protein output from an mRNA depends not only on its in-cell translation efficiency but
also how long it remains intact once transfected into cells. To assess the in-cell mRNA stability
of the library of constructs in a pooled fashion, PERSIST-seq quantifies the fractions of mRNAs
remaining at multiple timepoints following transfection of the library into cells. To ensure
recovery of intact full-length mRNAs rather than their degraded fragments, PERSIST-seq uses a
two-step protocol, first generating amplicons covering the entire CDS regions of mRNAs through
reverse transcription-PCR (RT-PCR) and then using primers flanking just the barcode region for
a second PCR before short-read Illumina sequencing to count intact mRNAs per time point (Fig
S1). Fits of an exponential decay function across the timepoints give an mRNA half-life (t1/2) for
each library construct.
For our library of 233 mRNAs, PERSIST-seq gives a wide dynamic range of in-cell
half-lives, ranging from less than 5 hours to over 15 hours (Fig. 2A). We had originally expected
that the sub-library comprised of varying 3‚Äô UTR sequences would give the most variation in
in-cell stability, since those mRNAs included diverse cis-regulatory elements that are known to
recruit cytoplasmic factors to aid or prevent mRNA decay53‚Äì56. However, surprisingly, we instead
observed the widest in-cell stability variation in the CDS and 5‚Äô UTR variant groups (Fig. 2A).
We also noted that constructs with higher ribosome load values tended to be more unstable
(Fig. 2B). More specifically, these unstable mRNAs include 5‚Äô UTR or 5‚Äô/3‚Äô UTR variants that
were heavily polysome shifted (Fig. 2B, polysome/monosome ratio). Increased association to
monosomes and thus a more moderate increase in overall ribosome load is positively
associated

with

mRNA

stability (Fig. 2B, monosomes/pre-polysome(pre-80S) ratios).

Importantly, these findings identify an unexpected rule for the design of mRNA ‚Äì excessively
increasing translation efficiency may negatively impact mRNA stability. Stated differently,
increased polysome load appears counterproductive to the goal of maximizing the total amount
of protein expressed over time.
To explore the implications of this apparent tradeoff, we sought to integrate both
translation (ribosome load) and in-cell stability (Fig. 2C) into a simple quantitative model to
understand and predict their relative impact on integrated protein expression (Fig. 2D-E)57. To
this end, we used differential equations to describe biochemical kinetics of mRNA translation
and mRNA/protein decay assuming first-order rate of translation and exponential decay for
mRNAs and for proteins. Below, M(t) and P(t) are moles of mRNA and protein at time t,
respectively; kt is translation rate; and km and kp are rates of mRNA and protein decay,
respectively:

9

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

ùëëùëÄ
ùëëùë°
ùëëùëÉ
ùëëùë°

=

‚àí ùëòùëö ¬∑ ùëÄ(ùë°)

= ùëòùë° ¬∑ ùëÄ(ùë°) ‚àí ùëòùëù ¬∑ ùëÉ(ùë°).

From these equations, the amount of protein at time t is proportional to the following (Fig. 2D):
‚àíùëòùëùùë°

ùëÉ(ùë°) ‚àº ùëòùë°

ùëí

‚àíùëò ùë°

‚àíùëí ùëö
ùëòùëö‚àíùëòùëù

.

This expression enables the ranking of expected protein levels across the UTR variants in our
mRNA library, as kt and km are related to from PERSIST-seq measurements of ribosome load
and in-cell half-lives, respectively, and the other parameters are known (Fig. 2E). Overall,
predicted protein expression per mole of transfected mRNA is modeled to be mostly driven by
the in-cell mRNA half-life (Fig. 2C, top panel), which more closely trends with predicted protein
expression (Fig. 2E) than ribosome load does (Fig. 2C, lower panel). To test this model, we
predicted and measured, using the luciferase readout, the protein levels observed at a given
time (here 12 hours post-transfection) when an equal mass of mRNA is transfected for each
sequence. Note that due to large length variations across tested UTR, the rank order of
predicted protein output per equal mass of transfected mRNA is shifted (Fig. 2E, bottom panel).
The predicted and measured luciferase activities showed a correlation of r = 0.71 (Fig. 2F),
supporting the accuracy of our model. However, for short expression (early time points after
mRNA transfection) or for ‚Äúabove-threshold‚Äù protein half-lives, translation can become the
dominant predictor. Therefore, depending on the desired parameters (early burst of high protein
expression or total protein output integrated over a longer time), the most optimal set of UTRs
can vary. Taken together, our large-scale and unbiased pooled measurement of translation and
mRNA stability provides a simple but powerful platform to test large numbers of different mRNA
sequence designs for desired protein expression and has allowed us to importantly infer that
in-cell mRNA stability is the dominant predictor of total protein output (Fig. 2C,E).
mRNA length and structure drive in-solution mRNA stability
The degradation of RNA in solution is a major obstacle in the distribution of mRNA therapeutics
to patients6. Thus, our final use of PERSIST-seq was to evaluate structure-based strategies for
optimizing RNA designs to be more stable in solution. Just as with the in-cell stability

10

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

measurements, we measured the fraction of mRNA CDS regions that remain intact after
degradation, taking advantage of the same RT-PCR to select for intact mRNAs, followed by a
PCR amplifying the short barcode regions in the 3‚Äô UTR (Fig. 1A, Fig. S1A, E). To mimic the
high effective pH and positively charged environment that can arise in lipid nanoparticles,
protamine, and other formulations for mRNA therapeutics6, we used a high pH buffer containing
Mg2+ to accelerate degradation (10 mM MgCl2, 50 mM Na-CHES, pH 10.0, 24 ¬∞C); conditions
without Mg2+ or at lower pH lead to similar conclusions on relative stabilities across RNA
variants (see below). The results for in-solution stability were strikingly different from the results
for in-cell stability across the mRNA library. For example, in cells, modulation of UTR sequence
produced large variation in in-cell stability (Fig. 2A), presumably through changes in recruitment
of cellular machinery that affect mRNA decay. In contrast, in aqueous solution without such
cellular machinery, changing the UTRs produced comparably little change in RNA stability to
hydrolytic degradation of the CDS (Fig. 2G).
The largest changes in in-solution stability occurred across CDS variants. The strongest
prediction of previous theoretical modeling7 was that length changes should drive the most
variation in in-solution stability, and PERSIST-seq data across different different CDS types
confirmed the effect of CDS length on RNA stability, (Fig. 2G). The shortest mRNAs in the pool,
encoding a multi-epitope SARS-CoV-2 vaccine CDS (MEV), exhibited in-solution half-lives of
3.4¬±0.6 hours. The longest mRNAs, encoding eGFP, exhibited much shorter in-solution
half-lives of 1.1¬±0.08 hours (Fig. 2G), as expected given the larger number of sites of potential
hydrolysis. Indeed, the ratio of these half-lives, 3.0¬±0.7, matched within error the inverse ratio of
the lengths of the mRNA regions captured by RT-PCR (958 nt/250 nt = 3.8), supporting
theoretical predictions of length effects.
The next largest source of variation in in-solution stability was driven by differences in
mRNA structure. Within mRNAs encoding for a single protein (Nluc, eGFP, or MEV), the
variance in in-solution half-lives was greater than for the variance across UTR variants (Fig.
2G), and these values correlated well with different metrics for predicted structure (see below).
The largest spread of in-solution half-lives (2.8-fold) occurred in the CDS variants for Nluc
mRNAs. We chose two Eterna-submitted solutions amongst these mRNAs with short and long
half-lives for follow up: ‚ÄòYellowstone‚Äô, a design using codons that mimic the base frequencies
(high A/C content) found in organisms found in the Yellowstone hot springs58; and
‚ÄòLinearDesign-1‚Äô, a design based on the LinearDesign mRNA structure optimization server46.
Chemical structure mapping showed that the long-lived LinearDesign-1 was significantly more
highly structured than Yellowstone, as assessed by dimethyl sulfate (DMS) and selective

11

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

2‚Äô-hydroxyl acylation with primer extension (SHAPE) reactivities59,60 (Fig. 2H, Fig. S3) and
structure models guided by these data (Fig. 2I). Overall, the global assessment of in-solution
RNA degradation using PERSIST-Seq reveals pronounced effects of RNA length and structure
on RNA half-life in solution.
Eterna-guided In-line-seq yields additional design principles and DegScore predictor
The mRNA designs above varied in-solution stability based mainly on computational predictions
of mRNA structure and the assumption that nucleotides that are not base paired in structure
would be uniformly prone to hydrolytic degradation7. We hypothesized that we might further
improve in-solution stability through a deeper understanding of any specific sequence and
structure features that lead to enhanced or suppressed hydrolysis in such unpaired regions. For
example, base identities and local structural features such as the size and symmetry of apical
loops and internal loops may play roles in determining in-solution mRNA degradation 61‚Äì63.
To test such effects and to potentially discover new ones, we challenged Eterna
participants to generate a large and diverse set of RNA molecules featuring designed secondary
structure motifs in a special challenge (‚ÄòOpenVaccine: Roll-your-own-structure‚Äô, RYOS). Limiting
the lengths of these molecules to 68 nucleotides and soliciting unique 3‚Äô barcode hairpins
enabled massively parallel synthesis and characterization of thousands of RNA molecules for
their

structure

and

degradation

profiles

(Fig.

3A).

In

particular,

we

obtained

single-nucleotide-resolution measurements of 3030 RNA fragments using In-line-seq, a version
of a low-bias ligation and reverse transcription protocol (MAP-seq)64 adapted here for in-line
hydrolysis profiles65 (Fig. 3B). This is the first massively parallel methodology and large-scale
data set applying in-line probing to RNA. For analysis of sequence and structure motifs,
sequences were filtered for low experimental noise and to ensure that the structure predicted in
ViennaRNA66 matched the structure inferred through SHAPE mapping data collected at the
same time (see Methods); these filters resulted in 2165 sequences and corresponding
secondary structures. We matched the accelerated degradation conditions used for
PERSIST-seq in-solution stability measurements, but also verified that measurements without
Mg2+, at lower pH, and higher temperature gave strongly correlated results (Fig. S4A). At a
broad level, the data confirmed that RNA structure was a dominant predictor of in-line hydrolysis
rate (compare, e.g., SHAPE to in-line data; Fig. S4A), but a closer look revealed additional
sequence and structure dependent rules for in-line hydrolysis.
When analyzed across known secondary structure motifs, the data revealed that the
RNA sequence in a given structure can dramatically affect degradation of the structure motif.

12

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

For example, in the case of the most-sampled secondary structure of triloops, the in-line
hydrolysis rates varied by up to 100-fold depending on sequence (Fig. S4B). Furthermore, in
many RNA loop types, it appeared that linkages that lead to a 3‚Äô uridine were particularly prone
to degradation (Fig. 3C, Fig. S4C), and this effect was reproduced in follow-up experiments
using capillary electrophoresis readouts (Fig. S4D). Thus, independent of the nucleotide identity
5‚Äô of the U, this bond is a hotspot for in-line nucleophilic attack63,65. In addition, we noted rules
for hydrolytic degradation that depended on the type of RNA structural loop in which a
nucleotide appears. A particularly salient characteristic was suppressed hydrolysis in symmetric
internal loops compared to asymmetric internal loops (Fig. 3C). To distill these observations into
a predictive model, we trained a windowed ridge regression model called ‚ÄòDegScore‚Äô based on
these In-line-seq data (Fig. 3D; see Methods) which quantitatively captured features like the
increased hydrolysis rates at linkages leading to 3‚Äô U (Fig. 3D). The DegScore regression
coefficients with the largest magnitude corresponded to the identity of the nucleotide 3‚Äô of a
linkage (Fig. 3D). Of these coefficients, G and C were the most favorable (least hydrolysis) to
have 3‚Äô of the linkage, followed by A, and a 3‚Äô U was most detrimental to degradation, matching
our prior observations.
To test the accuracy of the DegScore metric derived from In-line-seq data, we made
predictions of in-solution half-lives for the mRNAs measured in the PERSIST-seq experiments,
which were carried out completely independently (Fig. 1B, Fig. 2G). For the Nluc CDS variants
that showed the widest variance in in-solution half-lives, we observed a strong correlation of
DegScore predictions to the in-solution half-lives (Pearson R = -0.63, p<0.0001). Strikingly, the
accuracy of DegScore outperformed the accuracy of two other metrics that have been used in
prior studies to parametrize RNA structure but do not take into sequence or structure-motif
dependences of RNA hydrolysis: the free energy of the predicted minimum free energy
secondary structure, the metric used in several design algorithms including LinearDesign
(dGMFE; R = -0.53), and the predicted summed unpaired probability of the RNA structure
ensemble7 (SUP; R= -0.60) (Fig. 3E). Beyond the Nluc CDS variants, we confirmed that
DegScore gave the highest accuracy in predicting in-solution stability when evaluated over all
the measured mRNAs, including low and high structure eGFP mRNAs from Moderna
researchers, Eterna, and Ribotree (Table S1 and Fig. S5A,B).
Pseudouridine stabilizes RNA in solution
Given that the linkages with 3‚Äô U were particularly sensitive to degradation, we hypothesized
that the base chemistry of U may be directly linked to the degradative capacity of this

13

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

nucleoside and sought to test whether chemical alternatives to U might alleviate degradation. In
particular, we focused on œà and m1œà, since these substitutions for U have been widely adopted
for mRNA therapeutics and vaccines due to improved in-cell translation and to better control of
innate immune responses2,3,8,67 through avoidance of recognition by cellular toll-like receptors
(TLR7 and TLR8)68, RIG‚ÄëI, and PKR69‚Äì71. While œà and derivatives have been reported to
stabilize mRNAs against decay in cells67, the effects of these modifications on mRNA stability in
solution have not been reported. We selected RNA sequences from the Eterna RYOS challenge
(Fig. 3A) that were designed to contain U-rich loops or U-rich unstructured regions,
resynthesized these RNAs one-by-one with standard nucleotides or with œà or m1œà substituted
for U, and measured their in-line degradation over time via capillary electrophoresis. We
observed that substitution of U with either œà or m1œà led to remarkable suppression of in-line
hydrolysis at the substituted residues, presumably through changed nucleophilicity at the site of
substitution (Fig. 3F). We also observed suppression of in-line hydrolysis at nucleotides 1 to 2
positions 5¬¥ of the substitution (Fig. 3F), possibly due to locally enhanced base stacking72.
Structure mapping data based on SHAPE and DMS profiling confirmed that œà and m1œà
substitutions did not change the global structure of the RNAs; the suppression of in-line
hydrolysis appears to be due to local chemical or structural effects.
As a further test of this unexpected stabilizing effect, we prepared six constructs from the
233x-mRNA library with and without œà (Fig. 1, Fig. S5), including the LinearDesign-1 and
Yellowstone RNAs (Fig. 2I). In-solution degradation lifetimes were measured using capillary
electrophoresis to evaluate the fraction of intact mRNA after different timepoints (Fig. 3G-H).
Consistent with our in-line hydrolysis data on small RYOS RNAs, we observed a 1.2-2.7-fold
stabilization for these longer Nluc-encoding mRNAs when U was uniformly substituted with œà (
Fig. S5C). This finding indicated that beyond redesigning RNA sequences to take on stable
structure, in-solution RNA stability can be significantly further improved by incorporating
modified U nucleosides.
One-by-one tests confirm additivity of UTR, CDS, and œà improvements
Thus far we found that mRNAs harboring highly structured 5‚Äô and 3‚Äô UTRs can support high
levels of protein synthesis in cells. Moreover, using our RNA degradation predictor DegScore
and Eterna-derived designs, we saw that the highly structured CDSs can strongly affect both the
in-solution stability of mRNAs and their protein synthesis in cells (Fig. 2, Fig. 3). We next
investigated if selected UTRs and CDSs might be combined to achieve stable and highly
translated mRNAs that profit from additive effects of these individual improvements. In addition,
14

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

we investigated the use of œà in place of uracils to more thoroughly determine its effects on
stability and the overall translational output (Fig. 4).
We first determined the combined contribution of different CDS designs and UTRs on
mRNA stability and protein expression by choosing six CDS designs and three UTR
combinations from our high-throughput screen (Fig. 1A, Fig. 4A). The selected CDS designs
represented CDSs from diverse origins that support a range of observed in-solution half-lives
(from 0.69- to 1.8-fold relative to our reference ‚ÄòNluc start‚Äô sequence; Fig. 2G). We combined
these CDSs with different 5‚Äô and 3‚Äô UTRs in combination that were individually predicted and/or
confirmed (Fig. 2F) to facilitate the highest protein expression in our library (Fig. 2E-F). The
three UTR combinations comprised our standard hHBB 5‚Äô and 3‚Äô UTRs; a SARS-CoV-2 5‚Äô UTR
dSL-3 variant paired with the dengue virus 3‚Äô UTR, predicted to have high translational
efficiency but shorter in-cell half-life due to increased length; and C3 5‚Äô UTR paired with a SINV
U-rich element 3‚Äô UTR predicted to have good translational efficiency while reducing the size of
flanking sequence (Fig. 2E-F, Table S1). In terms of in-solution stability, we expected the
mRNAs with the longer UTRs to have consistently reduced half-life to hydrolytic degradation
across all 6 CDSs, and capillary electrophoresis experiments confirmed this expectation (Fig.
S6).
To quantitatively evaluate in-cell protein expression, the 18 mRNAs were individually
transfected and luciferase activity was measured after 6 hours (as an assessment of translation
rate before significant mRNA decay) and 24 hours (as an assessment of total protein output
after mRNA decay) (Fig. 4A). After 6 hours, two CDSs (LinearDesign-1 (Fig. 3) and GCrich_2)
achieved similarly high protein levels compared to Nluc start, when combined with hHBB 5‚Äô and
3‚Äô UTRs. The LinearDesign-1 result was striking given its unusual monosome-concentrated
polysome profile in PERSIST-seq (Fig. 1E) and the expectation that high mRNA structure
should adversely impact the cellular translational apparatus. The result was nevertheless
consistent with our model that enhanced in-cell half-life of a structured mRNA can compensate
for low translation efficiency (Fig. 2C-E). Indeed, by 24 hours, the mRNA with the
LinearDesign-1 CDS displayed an outstanding two-fold increase in luciferase yield compared to
that of Nluc start (Fig. 4A). LinearDesign-1 CDS mRNAs also exhibited a particularly long
in-solution half-life (Fig. 3G-H). Among the three UTR combinations and six CDS designs
tested, most demonstrated lower overall luciferase activity than the reference start Nluc with
hHBB UTRs (Fig 4A). One exception was the CoV-2-UUG-dSL-3/DEN2 UTR combination,
chosen based on its high performance for ribosome load (Fig. 2D-E), which was able to support
levels of protein synthesis at 6 hours nearly as high as the hHBB UTR for the LinearDesign-1
15

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

CDS; however this expression was lowered by 24 hours (Fig 4A). This finding is consistent with
faster mRNA decay compared to hHBB UTRs and our results supporting that in-cell mRNA
stability is a primary driver of protein output (Fig. 2C, E).
Given the improvements in in-cell stability we observed for pseudouridine (œà)-modified
RNA fragments and Nluc mRNAs, we further tested the effect of pseudouridylation on in-cell
stability and protein levels achieved from Nluc start vs. LinearDesign-1 CDS (Fig. 4A). As
expected, preparation of mRNAs with œà substituted for U led to increased in-solution stability
across both these CDSs, independent of UTR (Fig. S6). In terms of protein expression, we
observed variable effects on overall luciferase activity in the different UTR combinations with
fixed CDSs compared to unmodified mRNAs after both 6 and 24 hours of expression.
Importantly, both Nluc start and LinearDesign-1 CDSs with hHBB UTRs maintained high protein
expression at 6 and 24 hours (Fig. 4A) indicating that, despite œà modification and highly
structured CDSs, translation is sustained. Overall, these results demonstrated the importance of
mRNA stability to protein output, and suggested that the hHBB UTRs, highly structured CDSs,
and use of œà would be the best choices for increasing in-solution stability and protein output
moving forward.

Integration of all design rules leads to mRNAs with both high in-solution stability and
high protein output
For our final experiments, we sought to test whether further optimization, especially of the CDS,
might allow both enhanced in-solution mRNA stability and in-cell protein expression. To this end,
we collected a variety of CDS designs to compare to the Nluc start and Yellowstone mRNAs
from above, including (1) the default output of available mRNA design algorithms, including
those provided by Genewiz, Twist, and IDT websites and others that may enhance mRNA
structure (LinearDesign46 and use of GC-rich codons9), (2) highly structured constructs that were
rationally designed through an additional Eterna competition (‚ÄòOpenVaccine: Focus on the
NanoLuciferase mRNA‚Äô), and (3) output of the automated mRNA structure design tool Ribotree,
a stochastic optimization algorithm that can start from different seed sequences (random or
LinearDesign) and optimize in-solution hydrolysis lifetimes as guided by different predictors
(AUP, DegScore) (Fig 4B). From these approaches we generated 24 different CDS designs for
Nluc mRNA and, based on our studies above, we added the hHBB 5‚Äô and 3‚Äô UTRs as constant
regions to mediate high rates of translation initiation and used œà during synthesis due to its
enhancement of in-solution mRNA stability (Fig. 3F-G).

16

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

Each mRNA design was subjected to accelerated degradation and capillary
electrophoresis to measure the in-solution half-life of each individual CDS. Compared to the
Nluc start reference sequence, designs originating from Eterna exhibited up to 2.6-fold higher
in-solution half-life (see, e.g., RLT-10) while designs from commercial algorithms or optimized
GC-content tended to exhibit similar in-solution half-lives (Fig. 4C). Designs from the
LinearDesign server and modifications to these designs from both Eterna participants (e.g.,
AB_rhiju_mod3) and the RiboTree algorithm produced constructs with increased half-life up to
approximately 2.5-fold over the Nluc reference sequence (designs marked with triangles in Fig.
4C). In parallel to measurements of in-solution half-life, individual mRNA designs were assayed
for protein expression. Interestingly, despite overall longer in-solution half-lives, at 6 hours, both
Eterna- and Ribotree-derived designs tended to have similar or lower luciferase activities than
the reference Nluc sequence, whereas most vendor-derived and GC-rich designs had slightly
higher activities (Fig. 4C). At 24 hours, the trend of lower luciferase activity continued for 6 of 8
Eterna-derived designs tested compared to the Nluc reference mRNA (Fig 4C, green).
However, in contrast, 6 of 8 RiboTree-optimized mRNA designs demonstrated higher luciferase
activities than the Nluc reference mRNA at 24 hours (Fig. 4C, blue). Remarkably, the sequence
outputted by RiboTree starting from a LinearDesign CDS solution, with optimization guided by
DegScore and taking into account the flanking hHBB UTR sequences, yielded an mRNA that
was both highly stable in solution (t1/2 = 2.4, relative to Nluc start) and exhibited high levels of
protein

expression

in

cells

(1.7-fold

increase,

relative

to

Nluc

start)

(Ribotree_LinearDesign_degscoreall_1; Fig. 4C). This simultaneous increase in in-solution
stability with improved and sustained in-cell protein expression provided a strong demonstration
of the impact of our design rules for mRNA.
To gain insight into what led to success for this RiboTree_LinearDesign_degscoreall_1
sequence, we examined what changes RiboTree made as it computationally minimized the
DegScore metric from a starting LinearDesign server solution. Specific regions that RiboTree
modified from the starting sequence are indicated in Fig. 4D (with further comparison in Fig.
S7). These computational modifications are characterized by reducing the presence of Us in
loops, and shifting local base-pairing to minimize the overall size of loops, even if such shifts
result in additional smaller loops. These modifications are consistent with mitigating hydrolysis
as modeled in the DegScore predictor (Fig. 3D). Taken together, these data suggest that by
reducing the overall presence of Us in loops and reducing the number of hairpins to generate a
‚Äúlinear‚Äù highly double-stranded mRNA can lead to enhanced mRNA stability and protein
expression.
17

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

Correlating data from these final 12 Nluc RNAs provided additional insight into
biophysical and biophysical features impacting mRNA performance (Fig. 4, Fig S8). Most
notably, DegScore correlated strongly with measured in-solution half-life (R = ‚Äì0.55, p<0.001),
and moderately with 24 hour protein expression (R = ‚Äì0.47, p = 0.02), yet was uncorrelated with
6 hour protein expression (Fig. 4E). However, 6 hour protein expression correlated strongly with
the predicted number of hairpins (R = 0.70, p<0.001) and the ‚ÄúMaximum Ladder Distance73,‚Äù or
the maximum helix path length (R = -0.55, p<0.001) (Fig. S8C, Table S5). These observations
suggest that resistance to RNA hydrolysis, as predicted by DegScore and quantified by
in-solution half-life, is important for longer protein expression, but that other RNA sequence and
structural features govern protein expression at shorter timescales. For instance, longer or more
branched double-stranded RNA stems may potentially hinder the ability of the ribosome to
unwind RNA secondary structure.
In all our tests above, we measured in-solution half-lives of mRNAs using structural
readouts (reverse transcription-PCR; capillary electrophoresis), but sustaining functional output
after degradation is of strongest interest for mRNA applications. As a final experiment, we
therefore carried out an experimental stress test of in-solution stability with a functional readout
based on transfection and protein production in cells. For this ‚Äòend-to-end‚Äô test of mRNA
efficacy, we synthesized the original Nluc reference (Nluc start) mRNA alongside the optimized
Ribotree_LinearDesign_degscoreall_1 mRNA both with and without œà. Each individual Nluc
mRNA was then subjected to solution degradation, with 8 time points collected (Fig. 4F). As
expected

from

the

characterization

above

(Fig.

4C),

the

optimized

Ribotree_LinearDesign_degscoreall_1 mRNA exhibited higher resistance to degradation
in-solution than the Nluc Start mRNA and incorporation of œà into either mRNA further enhanced
in-solution stability, this time with a readout based on mRNA function in cells (Fig 4G). The
overall difference is striking: the majority of the mRNA stabilized with œà and a
structure-optimized CDS remains functional after 2 hours of accelerated solution degradation,
whereas our starting mRNA sequence gives negligible in-cell activity after the same degradation
(Fig 4G). Taken together, our detailed studies on individual mRNAs (Fig. 4) indicate that
combining UTRs that facilitate high levels of translation alongside structural optimization of
CDSs via LinearDesign and DegScore-guided RiboTree design, we can enhance both
in-solution stability and total in-cell protein output of mRNAs. Moreover, downstream luciferase
expression can be further amplified by œà modification of mRNAs. These results validate and
demonstrate a modular and flexible platform that is applicable to potentially any protein target of
choice and can accelerate the design of overall improved mRNA therapeutics solutions.
18

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

DISCUSSION
mRNA-based therapeutics are transforming the way in which human disease is treated,
particularly infectious disease (e.g. the timely COVID-19 mRNA vaccines)74‚Äì77. However, there
still remain several major hurdles that need to be overcome for mRNA-based therapeutics to be
effective, many of which are directly linked to the intrinsic features of mRNA as a molecule. In
particular, RNA is inherently unstable due its 2‚Äô-hydroxyl group, and degradation of the mRNA in
solution by in-line nucleophilic attack, potentially aggravated by formulations, poses a major
challenge6. Moreover, once delivered into patient cells, the candidate mRNA must outcompete
other cytoplasmic mRNAs for the translation machinery and avoid the cellular mRNA
degradation machinery to express maximum amounts of the desired encoded protein. Our study
presents advances in tackling both of these challenges, building on two new high-throughput
technologies.
Our first set of experimental findings derive from the integrated PERSIST-seq
technology, which enables massively parallel evaluation of the effects of UTR and CDS
sequence and structure on in-cell mRNA translation efficiency, in-cell mRNA stability, and
in-solution stability. This technology identifies previously unknown tradeoffs and additive effects
between different tunable aspects of mRNA performance as key determinants. Most important
for optimizing these characteristics and their interdependencies, we find that in-cell mRNA
stability may be a greater driver of protein output than high ribosome load particularly when
proteins need to be expressed from a single dose of mRNAs for long periods of time. In
particular, high translation efficiency mRNAs associated with the heaviest polysomes tend to be
less stable: there is a ‚Äòsweet spot‚Äô for translation efficiency for maximal total protein output. This
effect may derive from overcrowding of ribosomes on mRNA coding regions due to rapid
initiation, which can induce sterical ribosome collisions that have recently been found to lead to
translation-dependent mRNA decay78,79. Understanding this phenomenon is an exciting prospect
for future mechanistic studies. Overall, we observed a wide range of UTR-dependent translation
efficiencies in PERSIST-seq which could be further fine-tuned with specific UTR sequence or
CDS structure alterations. We note that for applications with very short mRNAs (as are in use
for multi-epitope cancer vaccines, and represented in our MEV sequences80) or much longer
mRNAs (as are needed for antigens like the SARS-CoV-2 Spike protein), the best UTRs and the
sweet spot for optimal translation efficiency may be different. In this respect, certain UTR
combinations outperform hHBB in translation efficiency and include multiple cellular 5‚Äô UTRs as

19

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

well as, unexpectedly, the dengue virus 5‚Äô and 3‚Äô UTRs, which both individually increase
ribosome loading, and combining them in one mRNA resulted in an additive effect. As illustrated
with the SARS-CoV-2 5‚Äô UTR, selective translational enhancers can be further identified through
careful mutagenesis and deletion strategies aimed at narrowing selective regulatory regions
within viral leader sequences. We also note that our experiments were limited to HEK293T as
model human cells; the best UTRs for high protein output are likely to be cell-type dependent
and therefore will vary from application to application. Our library of UTRs and the PERSIST-seq
technology should be well-suited for discovering and leveraging the optimal UTRs for future
applications with different protein targets and different cell types.
Our second set of experimental improvements relate to mRNA stability in aqueous
solution. PERSIST-seq confirms predictions that extremely highly structured mRNAs can exhibit
more than double the in-solution half-lives of conventionally designed mRNAs, with strong
implications for improved storage in solution. Further design insights came from a new method
called In-line-seq for high-throughput in-line probing63,65, applied to thousands of diverse short
RNAs derived from the Eterna crowdsourcing platform. The In-line-seq results reveal a number
of structural rules for mitigating in-solution RNA hydrolysis as well as simple sequence rules: a
key determinant of in-solution RNA degradation is the presence of uridine and that RNA
linkages 5‚Äô of a uridine residue are particularly susceptible to degradation. Interestingly, this
effect can be alleviated through inclusion of the nucleoside modification œà or m1œà. Synthesis of
mRNAs with modifications ‚Äì already in wide use for mitigating innate immune response and
translational shutdown by mRNA therapeutics67,68,74,75 ‚Äì is therefore a simple method to achieve
significantly greater in-solution stability while sustaining protein expression.
Further leveraging our in-line hydrolysis data, we developed DegScore, a model for
hydrolytic degradation that was independently validated on PERSIST-seq data and which
enables in silico optimization of any RNA sequence. By combining optimal UTRs, DegScore
optimization with RiboTree, and œà modification, we are able to achieve high mRNA stability and
improved protein expression. We note that DegScore was trained on degradation from
unmodified nucleotides that does not account for our observed stabilization via œà. Thus, future
studies training similar models on degradation data from œà and other nucleoside modifications
may result in improvements to CDS stabilization via algorithmic design. We also note that our
study has focused on characterizing degradation of naked, non-formulated mRNAs in order to
understand limitations on stability imposed by the fundamental biophysical and biochemical
properties of RNA; such non-formulated mRNAs also appear optimal for certain applications
including personalized cancer mRNA vaccines81. For applications that benefit from mRNA

20

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

formulated in lipid nanoparticles or other carriers, we expect future studies applying
PERSIST-seq and In-line-seq to formulated mRNA libraries to reveal additional powerful
insights. Lastly, it has been proposed that highly structured mRNAs may retain their structure
and in-solution stability under temperature shifts, mutations, and changes in UTRs, motivating
the term ‚Äòsuperfolder‚Äô mRNAs7; it will be interesting to test these predictions through future
PERSIST-seq studies.
Overall, we report a new mRNA design methodology that can dramatically enhance
mRNA stability in aqueous solution while sustaining or even increasing protein expression
inside cells. There does not have to be a tradeoff between mRNA structure, stability, and protein
output. Looking ahead, our computational and experimental methods provide a platform to
rapidly develop customized highly structured mRNAs for novel target proteins. As mRNA-based
medicines are explored for a wide range of human diseases including cancer therapies, we
hope that these insights and methods can help these medicines become more effective,
manufactured at lower cost per patient, and more accessible and widely distributed to alleviate
disease.

21

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

SUPPLEMENTAL TEXT
In-cell 5‚Äô UTR sequence selection to determine rules of efficient translation initiation
Beyond comparing full UTR and CDS regions, we further sought to select for an optimally
translating 5‚Äô UTR sequence in an unbiased fashion from a complex sequence library (Fig. S2).
Similar to sequence selection by enrichment through direct binding82 previously performed for
mRNA-stabilizing 3‚Äô UTR sequences18, we selected for highly translating transcripts by
transfecting an mRNA reporter library with varying 5‚Äô UTR sequences and harvesting mRNAs
associated with heavy polysomes (Fig. S2A). We further enriched these libraries for highly
translating transcripts over a total of five rounds of selection and re-transfection of the heavily
ribosome loaded mRNAs from two independent starting pools (Fig. S2A, B). We compared
them to input sequences of the initial and fifth selection round by RNA-seq. Using the hHBB 5‚Äô
UTR as our baseline (Fig. S2A), our 5‚Äô UTR library design used the first 29 nt of the hHBB 5‚Äô
UTR followed by a 35 nt stretch of random sequences (N35, N=A,C,T,G) and the consensus
Kozak sequence (GCCACCAUGG)83,84 upstream of the Nluc ORF.
First, we asked whether 5‚Äô UTRs selected to be polysome-associated would increase the
protein output compared to hHBB. We chose candidate 5‚Äô UTRs in which we observed high
read counts in the final round (‚â•15 reads), increasing representation across all selection rounds
(FDR‚â§0.1), and >2-fold enrichment in the last round of selection compared to its input (Fig.
S2C) and performed luciferase reporter assays with these mRNAs (Fig. S2D). Beside a wide
range of luciferase activity driven by candidate 5‚Äô UTR mRNAs, we surprisingly observed that
none demonstrated luciferase activity that was significantly higher compared to hHBB 5‚Äô UTR.
Thus, although we are selecting for 5‚Äô UTR reporter mRNAs of highest ribosome load, this
unexpectedly decreases total protein output, which suggests the selected 5‚Äô UTRs may have
also impacted mRNA stability or translation elongation kinetics; a similar tradeoff is reported in
the PERSIST-seq measurements described in the main text (Fig. 2).
To determine common features among the selected 5‚Äô UTR sequences, we calculated
position-specific short k-mer enrichment across the N35 region using kpLogo85 (Fig. S2E). We
observed stronger enrichment/depletion of specific k-mers (165,611 k-mers tested in total)
towards the 5‚Äô and 3‚Äô ends of the N35 stretch (Fig. S2E). In a confirmatory observation expected
from ribosome scanning model of translation initiation, AUG triplets are significantly depleted
across the N35 region (Fig. S2F). This effect is periodic and specific to two out-of-frame (frames
1 and 2) AUGs while in-frame AUG (frame 0) is not strongly affected, suggesting the negative
impact of the competing upstream start codon except when it is in-frame to result in an
N-terminally extended ORF and protein product. A variety of other interesting motifs are further
22

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

observed, such as the depletion of guanine repeats (for example depletion of GGGG or GGG at
the 3‚Äô end of the N35, close to the fixed Kozak consensus) and uridine repeats throughout the 5‚Äô
UTR and enrichment of specific k-mers that suggest formation of short stem-loop structures
promoting translation (Table S3). The latter is especially striking: for example, the 6-mer
GUGAAC is strongly enriched towards the 5‚Äô positions of the variable N35-mer region;
GUGAAC is reverse complement to the last 6 nucleotides of the fixed HBB-29 region
(GUUCAC), which would therefore be able to perfectly base-pair with each other and comprises
an inverted repeat (Fig. S1G). The enrichment of the 6-mer peaks at the 4th to 6th nucleotide
position downstream of the HBB-29 region, thus favoring an intervening length of 3 nt that would
allow a 3-nt loop to form after base-pairing with the 6-mer stretches. Examining other possible
inverted repeat k-mers in the variable region as 6-mer reverse complements sliding along the
fixed region, we find that the stem may be formed up to around position -30 to the AUG. Such a
pattern indicates that folding of a small stem-loop in the middle of the 5‚Äô UTR under selection
may actually be favored in mRNAs with heavy polysome load. This finding is in contrast to the
typical expectations for secondary structures in 5‚Äô UTRs to generally repress translation
initiation. This finding is interesting because some synthetic small 5‚Äô UTR RNA hairpins have
previously been found to improve protein expression86. In sum, our sequence selection strategy
formalizes previously predicted rules for 5‚Äô UTR sequences that optimize ribosome load, and
motivates an integrated approach to optimization of protein expression that jointly leverages our
ribosome load dataset (Fig. 1) in parallel with our study of in-cell mRNA stability (Fig. 2).

23

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

FIGURES
Figure 1

24

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

Figure 1. PERSIST-seq overview and illustrative ribosome load insights.
(A) Overview of the mRNA optimization workflow. Literature mined and rationally designed 5‚Äô
and 3‚Äô UTRs were combined with Eterna and algorithmically designed coding sequences. All
sequences were then experimentally tested in parallel for in-solution and in-cell stability as well
as ribosome load. The mRNA design included unique, 6-9 nt barcodes in the 3‚Äô UTR for tag
counting by short-read sequencing.
(B) Experimental design for testing in-solution and in-cell stability and ribosome load in parallel.
mRNAs were in vitro transcribed, 5‚Äô capped, and polyadenylated in a pooled format before
transfection into HEK293T cells or being subjected to in-solution degradation. Transfected cells
were then harvested for sucrose gradient fractionation or in-cell degradation analysis.
(C) Polysome trace from transfected HEK293T cells with 233-mRNA pool.
(D) 5‚Äô UTR variants display a higher variance in mean ribosome load per construct as
determined from polysome sequencing. The formula for ribosome load is given.
(E) Heatmaps from polysome profiles of mRNA designs selected from the top, middle, and
bottom five mRNAs (by ribosome load) from each design category.
(F) Secondary structure model of the SARS-CoV-2 5‚Äô UTR. Introduced mutations and
substitutions are highlighted.
(G) Heatmaps of SARS-CoV-2 5‚Äô UTR variants‚Äô polysome profiles sorted by ribosome load.

25

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

Figure 2

26

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

Figure 2. In-cell RNA stability drives downstream protein expression levels.
(A) In-cell half-life of each mRNA design in HEK293T cells.
(B) Higher polysome load correlates with decreased in-cell half-life. Correlation between in-cell
half-life and mean ribosome load across the entire profile (left), monosome-to-free subunit ratio
(center), or polysome-to-monosome ratio (right).
(C) In-cell half-life and mean ribosome load for individual mRNA designs with varying UTRs.
(D) Kinetic model for predicting protein expression from mRNA half-life and ribosome load. P(t)
is protein quantity at time t; m0 is the mass of mRNA present at t=0; l is mRNA length; kt is
translation rate; and km and kp are rates of mRNA and protein decay, respectively.
(E) Protein expression predicted using the kinetic model in (D) on the basis of mRNA half-life
and ribosome load. Top: predicted protein expression of each UTR variant; note closer similarity
to in-cell half-life data than to ribosome load in (C). Bottom: predicted protein expression
normalized by mRNA length (corresponding to transfecting equal masses of each mRNA).
(F) Correlation of predicted protein expression and Nluc/Fluc activity in HEK293T cells.
(G) In-solution half-life of various mRNA design variants. mRNA lifetimes are strongly
dependent on mRNA length and designed structures, revealed by time courses of mRNA
degradation under accelerated aging conditions (10 mM MgCl2, 50 mM Na-CHES, pH 10.0).
(H) Nucleotide-resolution in vitro DMS mapping confirms large differences in structural
accessibility between a highly structured JEV-HA-Nluc mRNA construct, ‚ÄúLinearDesign-1‚Äù and a
highly unstructured construct ‚ÄúYellowstone‚Äù. The 5‚Äô and 3‚Äô UTRs (hHBB) were kept constant
between designs.
(I) Nucleotide DMS accessibility mapped on to structures from DMS-directed structure
prediction.

27

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

Figure 3

28

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

Figure 3. High-throughput in-line hydrolysis uncovers principles of in-solution RNA
degradation.
(A) Eterna participants were asked to design 68-nucleotide RNA fragments maximizing
sequence and structure diversity. 3030 constructs were characterized and probed using
high-throughput in-line degradation (In-line-seq).
(B) Nucleotide-resolution degradation of 2165 68-nt RNA sequences (filtered for signal quality),
probed by In-line-seq, sorted by hierarchical clustering on degradation profiles.
(C) Sequences span a diverse set of secondary structure motifs, revealing patterns in
degradation based on both sequence (i.e., linkages ending at 3‚Äô uridine are particularly reactive)
and structure (symmetric internal loops, circled, have suppressed hydrolytic degradation
compared to asymmetric internal loops).
(D) The ridge regression model ‚ÄúDegScore‚Äù was trained to predict per-nucleotide degradation
from sequence and loop assignment information. Coefficients with the largest magnitude
corresponded to sequence identity immediately after the link, with U being most disfavored.
(E) DegScore showed improved predictive power on mRNAs over two other metrics previously
posited to predict RNA stability.
(F) Introduction of pseudouridine (œà) modifications stabilizes selected short RNAs at U
nucleotides in both loop motifs and in fully unstructured RNAs.
(G) Capillary electrophoresis characterization of fragmentation time courses of Nluc mRNA
molecules designed with extensive structure (LinearDesign-1) and relatively less structure
(Yellowstone), synthesized with standard nucleotides and with œà modifications. The full-length
mRNA band is indicated with a red asterisk. The Tetrahymena ribozyme P4-P6 domain RNA
was included after degradation as a control.
(H) Exponential fits of capillary electrophoresis measurements of intact RNA over ten time
points confirm >3x difference between in-solution lifetimes of LinearDesign-1 and Yellowstone
Nluc mRNAs. Inset: Calculated half-lives. Error bars represent standard deviations from
bootstrapped exponential fits (n = 1000).

29

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

Figure 4

30

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

Figure 4. Integration of 5‚Äô/3‚Äô UTRs, structure-optimized CDSs, and pseudouridine (œà)
together enhance mRNA stability and translational output.
(A) CDS and 5‚Äô/3‚ÄôUTR combinations differentially impact protein synthesis. Six mRNA
constructs were in vitro synthesized and luciferase activity was measured 6 or 24 hrs
post-transfection. Inclusion of œà was tested on two selected constructs.
(B) Workflow for different approaches to design the CDS variants tested in (C).
(C) Variations in CDS design facilitates high in-solution stability and differential protein
expression. In vitro transcribed mRNAs (24 in total) were subjected to in-solution degradation or
transfected into HEK293T cells for 6 and 24 hrs. In-solution half-lives and luciferase activity are
normalized to the Nluc START reference construct. Predicted secondary structures are shown
for select constructs with colors indicating DegScore at each nucleotide. Designs derived from
LinearDesign solutions are marked with a purple triangle.
(D) Predicted secondary structure overview of Ribotree_LinearDesign_degscoreall_1. Zoomed
boxes indicate sequence optimizations and subsequent structural changes made by DegScore
to the reference LinearDesign construct.
(E) Increased in-solution half-life and enhanced luciferase expression at 24 hrs, but not 6 hrs,
correlate with DegScore.
(F) Schematic for testing the synergy between RNA modifications and mRNA design rules on
downstream stability and protein output. mRNAs were in vitro synthesized with or without œà and
subjected to degradation conditions. Samples were collected overtime and the RNA was
purified before being transfected into HEK293T cells. Luciferase activity was measured 24 hrs
after transfection.
(G) Luciferase activity of the reference Nluc sequence and DegScore-optimized CDS with or
without œà after being subjected to in-solution degradation.

31

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

SUPPLEMENTAL FIGURES and FIGURE LEGENDS
Supplemental Figure 1

32

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

Figure S1. mRNA reporter design and in-cell and in-solution workflows with in-cell
polysome validation.
(A) Schematic for the 3‚Äô UTR-barcoded mRNA reporter used to screen mRNA performance in a
pooled format. The constant regions and barcode, which flank a variable 3‚Äô UTR, were
instrumental for amplifying and identifying hundreds of constructs simultaneously in each of the
pooled experiments that comprise PERSIST-seq. The DNA templates for full-length mRNAs
were synthesized on the Codex platform and amplified in a pooled PCR using primers
complementary to the constant region (T7 promoter) preceding the variable 5‚Äô UTR, and to the
‚Äòconstant3‚Äô region following the variable 3‚Äô UTR.
(B) Summary of the workflow to progress from the individually synthesized DNA templates to
the in vitro synthesized mRNA pool of 233 different constructs. We then use the same mRNA
pool to screen mRNA performance in a three-pronged set of in-cell and in-solution expression
and stability analyses.
(C) Quality control of the 233-mRNA pool on a 1.2% formaldehyde (FA) gel stained with
ethidium bromide (EtBr) after 3 hrs of in vitro transcription (IVT). The mRNA pool was analyzed
before and after capping and polyadenylation. Pooled IVT is equally efficient with the starting
template DNA pool with or without PCR-amplification of the DNA template pool. The three major
bands corresponding to the three CDS types are indicated. The RiboRuler High Range RNA
ladder (Thermo Fisher) is loaded for reference.
(D) Polysome fractionation analysis of a transfected mRNA reporter. As an example, the
distribution of an mRNA with short scrambled 5‚Äô and 3‚Äô UTRs 6 hrs after transfection into
HEK293T cells was compared to the distribution of endogenous human ActB mRNA. RNA was
extracted from fractions and quantified by qPCR with a RNA spike-in for normalization. Values
are plotted as mRNA normalized per fraction.
(E) In-solution RNA degradation strategy of barcoded mRNAs containing CDS variants with
hHBB 5‚Äô and 3‚Äô UTRs. The differential degradation of CDS variants depends on their individual
CDS structures. mRNA pools are degraded in solution by nucleophilic attack (red circle). After
degradation, RT-PCR is performed to selectively amplify mRNAs that remain intact along their
full length. Then, the barcode regions of these full-length mRNAs are PCR-amplified,
adaptor-ligated, and prepared for Illumina sequencing.

33

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

Supplemental Figure 2

34

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

Figure S2. Sequential selection of high ribosome loaded mRNAs uncovers 5‚Äô UTR
sequences that contribute to protein abundance.
(A) Overview of the in-cell selection assay designed to uncover 5‚Äô UTR sequences that
contribute to translational efficiency. First 29 nt of the human HBB 5‚Äô UTR was chosen as the
fixed 5‚Äô region followed by the 35 nt long degenerate region and a constant Kozak consensus
sequence (GCCACC). Selection of the variable 35 nt region is introduced by subsequent
re-transfection of only the mRNAs purified from the heavy polysomal fractions.
(B) Denaturing urea-polyacrylamide gel for the quality control of the in vitro transcribed mRNA 5‚Äô
UTR selection library before and after the 5‚Äô cap and polyA-tail, shown for the selection round 0.
All consecutive selection rounds yielded similar libraries. The Low Range ssRNA Ladder (NEB)
was loaded for reference. The gel was stained with SYBR Gold (Thermo Fisher).
(C) Normalized reads per million (RPM) of the top 5‚Äô UTR sequences (FDR‚â§0.1) over the
course of the selection rounds. Colored lines indicate mRNAs that were chosen for luciferase
reporter assays (15 in total from two independent starting pools; ‚â•15 final round read count,
‚â•2-fold final round enrichment over input).
(D) Normalized Nluc/Fluc luciferase activities of the top 15 mRNAs from (C). The 35-nt variable
region in the 5‚Äô UTR of the polysome selected mRNAs are listed along the y-axis. Their
luciferase activity is plotted on the x-axis relative to hHBB. HBB-29 contains only the first 29 nt
of the hHBB 5‚Äô UTR.
(E) Boxplot of all log2 odds ratios of k-mers (2‚â§k‚â§6) between the final polysome selection round
and the initial starting pool. Higher variations are observed towards either 5‚Äô/3‚Äô ends of the 35 nt
variable region. Most of the significant k-mers in the 3‚Äô positions are depletions.
(F) Depletion of out-of-frame (+1- and +2-frames) AUGs within the 35 nt variable region
following the polysome selection rounds. In-frame AUGs (0-frame) are weakly depleted or even
show minor enrichment closer to the 3‚Äô end.
(G) Enrichment of the 6-mer motif GUGAAC following polysome selection. GUGAAC is reverse
complementary to the 3‚Äô end of the fixed 29-nt region of the 5‚Äô UTR (GUUCAC). The enrichment
towards the 5‚Äô end of the variable region and its peak at the 4th to 6th nucleotides downstream
of the end of the fixed region may indicate favorability of small stem loop structure for increased
ribosome loading.

35

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

Supplemental Figure 3

Figure S3. Chemical structure probing of Yellowstone and LinearDesign-1 RNAs.
(A) SHAPE and DMS reactivity per sequence position of Yellowstone and LinearDesign-1.
(B) MFE structures derived using SHAPE reactivity.

36

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

Supplemental Figure 4

37

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

Figure S4. Features of RNA degradation as determined by In-line-seq.
(A) Correlation of summed in-line degradation per construct at pH 10, 25ÀöC, [Mg2+] = 10 mM, 1
day conditions, to SHAPE reactivity and other in-line degradation conditions tested.
(B) Dynamic range of average reactivity for hairpin loop degradation for in-line degradation at
pH 10, 25ÀöC, [Mg2+] = 10 mM, 1 day conditions.
(C) Sequence/location dependency of triloop reactivity and degradation for other three
experimental in-line degradation conditions tested (see Fig. 3C).
(D) In-line degradation for 8 constructs measured one-by-one with capillary electrophoresis, in
absence and presence of pseudouridine. Left panel depicts nucleotides predicted to be
unpaired, right panel depicts nucleotides predicted to be paired in ViennaRNA structure.

38

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

Supplemental Figure 5

Figure S5. Correlation between the 233-mRNA pool in-solution half-life and predictors for
RNA degradation.
(A) Correlation between in-vitro half-lives and dG(MFE), Sum p(unpaired) calculated in
ViennaRNA and EternaFold, and DegScore across all model mRNA types tested.
(B) Correlation between in-vitro half lives, normalized to RNA length, and dG(MFE), Average
p(unpaired) (AUP) in ViennaRNA and EternaFold, and DegScore across the Nanoluciferase and
eGFP constructs.
(C) One-by-one characterization of in-vitro half-lives of 6 model mRNAs, characterized with U
and with pseudouridine.

39

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

Supplemental Figure 6

Figure S6. Effect of UTR and modified nucleosides on in-solution half-life.
(A) 6 select CDS designs were combined with three different pairs of 5‚Äô and 3‚Äô UTRs and the
in-solution

half-lives

were

measured.

The

half-life

of

‚ÄòNluc

start‚Äô

with

CoV-2-UUG-UUGfull-dSL1-3/DEN2 UTRs (red arrow) could not be accurately measured as it
was outside the dynamic range of the experiment; data represent an upper bound.
(B) Two model RNAs from Panel A were synthesized with pseudouridine and in-solution
half-lives were measured. The half-life of ‚ÄúLinearDesign-1‚Äù with hHBB/hHBB UTRs containing
pseudouridine (red arrow) was not accurately captured as this RNA persisted beyond the range
of the experiment; data reflect an approximate upper bound.
Error bars indicate standard deviations from 1000 bootstrapped exponential fits for half-life
calculation

40

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

Supplemental Figure 7

41

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

Figure S7. Overview of predicted RNA secondary structures of constructs in Fig. 4C.
(A) Predicted secondary structures of final tested Nanoluciferase constructs, colored by AUP.
(B)

Comparison

of

secondary

structure

of

starting

RiboTree_LinearDesign_degscoreall_1 and annotations of changes.

42

sequence

used

for

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

Supplemental Figure 8

43

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

Figure S8. Correlation of experimental data for 24 Nluc constructs to predicted
degradation and structure metrics.
Correlation of normalized in-solution half-life, normalized Nluc expression at 6 hours and 24
hours, tested for correlation to (A) GC content; (B) CAI; (C) number of hairpins; (D) Maximum
ladder distance, the maximum length of contiguous helices in the secondary structure; (E)
SUP(14 init.), the summed unpaired probability of the first 14 nucleotides; (F) dG(MFE); (G),
AUP (average unpaired probability); (H) DegSore. Notably, AUP and dG(MFE) have higher
correlation to in-solution half-lives than DegScore; this is possibly because the DegScore model
was not trained with data on pseudouridine.

44

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

ACKNOWLEDGEMENTS
We would like to thank the Barna and Das lab members for support and constructive criticism
and reading of and helpful comments on the work, and Eterna Players for providing sequences
and for critical reading of the manuscript. Eterna participant usernames and full names, when
volunteered, are provided in Table S7. We thank Ramya Rangan for advice on SARS-CoV-2
structure. We thank Ivan N. Zheludev for performing pilot experiments. We are grateful to
Kelsey L. Hickey and Jonathan S. Weissman (UCSF, San Francisco, CA, USA); and Conor J.
Howard (UCSF, San Francisco, CA, USA) for kindly sharing plasmids. We would like to thank
John Coller and Dhananjay Wagh of the Stanford Functional Genomics Facility (SFGF), and
Michael Eckart, Kyle Fukui and Jennifer Okamoto (Protein and Nucleic Acids Facility) for
experimental support. We thank Liang Huang (Oregon State University, Baidu Research USA)
for discussions of LinearDesign. RiboTree calculations were performed on the Stanford
Sherlock cluster. We thank Camilla Kao, Howard Y. Chang (Stanford University); Hani Choudhry
(King Abdullaziz University); Anthony Goldbloom, Maggie Demkin, and Walter Reade (Kaggle,
Inc.); and Dani Braun, Austin Chen, Sharif Ezzat, Abhi Garg, Johannes H√§ggqvist, Tamas
Kalman, Kevin Lin, and Amine Rehioui for development and advice important for launching
online components of the OpenVaccine challenges. We thank Helga Leppek for providing the
Barna lab with handmade masks at the onset of the pandemic for essential lab work and Lisa
Sharp and Jessica Corkern (Stanford Biochemistry Department) for supporting Das laboratory
experiments. This work was supported by NIH grants R01HD086634 (M.B.) and R35
GM122579 (R.D.), the National Science Foundation GRFP (H.K.W.S., D.S.K.), a Benchmark
Stanford Graduate Fellowship (G.W.B, C.A.C.), a Stanford ChEM-H ‚ÄúStanford RISE'' seed grant
(H.K.W.S.), a Canadian Institutes of Health Research Postdoctoral Fellowship (C.K.), Paul and
Daisy Soros Fellowships for New Americans (G.C.T), Stanford Medical Scientist Training
Program (A.X., G.C.T.), and a Human Frontier Science Program Fellowship (K.F.). D.R. is
supported by an EMBO Long-term Fellowship (ALTF 1042-2019) and a Human Frontier Science
Program Fellowship (LT000218/2020-L). A.X. is supported by a Stanford Bio-X/SIGF fellowship
and NIH fellowship 1F30HD100123. K.L. is supported by an EMBO Long-Term Fellowship
(ALTF 539-2015), is the Layton Family Fellow of the Damon Runyon Cancer Research
Foundation (DRG-2237-15), and is supported by the Katharine McCormick Advanced
Postdoctoral Scholar Fellowship to Support Women in Academic Medicine (2019). M.B. is a
New York Stem Cell Foundation Robertson Investigator. Further financial support came from
gifts to the Eterna OpenVaccine project from donors listed in Table S8.

45

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

METHODS
In vitro transcription of reporter mRNAs
Preparation of mRNAs were based on in vitro transcription from DNA templates. DNA templates
were amplified by PCR using AccuPrime Pfx (Life Technologies, 12344024) and purified using
the Monarch PCR & DNA Cleanup Kit (NEB, T1030L). The source of the 3xHA-Nluc starting
CDS (‚ÄúNluc start‚Äù) is derived from the pcDNA3.1-5'UTR-3xHA-Nluc plasmid encoding the
HA-tagged Nanoluc CDS43. Individual template DNA or the 233-mRNA library was amplified
from linear DNA synthesized on a BioXP 3200 system (Codex DNA) or by Twist Bioscience,
using the fixed forward (T7_F_28nt) and reverse (const3_R) primer. The forward primer binds to
the T7 RNA polymerase promoter common in DNA template for all mRNA designs; the reverse
primer is complementary to a common ‚Äúconst3‚Äù region at the end of all tested mRNA 3‚Äô UTRs.
For the IVT template pool, individual DNA templates were pooled for a template pool of
hundreds of constructs at an equimolar concentration and are amplified with outer primers in a
pooled format. For the pooled template, 1 ¬µL of each construct (~20 ng/¬µL stock concentration)
was pooled to be used as the PCR template. The Pfx PCR contained the following: 2.5 ¬µL 10x
Pfx buffer, 0.25 ¬µL forward primer (100 uM), 0.25 ¬µL reverse primer (100 uM), 0.75 ¬µL DMSO
(NEB), 0.25 ¬µL Pfx Polymerase (Thermo), 20.5 water, and 0.5 ¬µL template DNA (~20-50 ng/ul),
in a total 25 ¬µL reaction with the following program: 2 min at 95¬∞C; 10 sec at 95¬∞C; 30 sec at
58¬∞C; 30s or 1 min at 68¬∞C; cycled 9x; final extension of 5 min at 68¬∞C. PCR reactions were
purified with Monarch PCR & DNA Cleanup Kit (NEB, T1030L). For the hHBB-Fluc control
mRNA, the DNA template was amplified from the pGL3-HBB plasmid87 using the primers
KL588/KL589 which yielded a PCR product of 1,750 kb in length. For cloning the MALAT1 ENE
3‚Äô UTR stem-loop, we first amplified the ENE region using primers ENE-1/ENE-2 with flanking
constant regions. The resulting amplicon was assembled with a hHBB-Nluc sequence that
lacked a 3‚Äô UTR but maintained a unique barcode using a NEBuilder HiFi Assembly Kit (NEB,
ES2621).
In vitro transcription was performed with the MEGAscript T7 kit (Ambion, AM1333)
according to the manufacturer‚Äôs instructions. A 20 ¬µL transcription reaction contained max. 5 ¬µg
linear DNA template, 4 mM of each NTP (Ambion), 2 ¬µL/ 200 U MEGAscript T7 RNA
polymerase (Ambion) and 1x T7 MEGAscript Transcription Buffer (Ambion). After a total
incubation for 3 hours at 37¬∞C, the DNA was digested by addition of 1 ¬µL/2 U Turbo DNase
(Ambion, AM2238) for 15 min at 37¬∞C. For pseudouridylated mRNAs, pseudouridine
triphosphate (Trilink Biotechnologies, N1019-5) was substituted for uridine triphosphate at an

46

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

equivalent concentration. mRNA was purified using MegaClear columns (Thermo Scientific,
Ambion, AM1908). A 20 ¬µL reaction usually yielded 100-150 ¬µg of RNA.
For mRNA transfection of HEK293T cells, m7G-capped and polyadenylated mRNAs
were generated as follows. In vitro transcribed mRNA was then m7G-capped and
polyadenylated using the ScriptCap m7G Capping System (CellScript, C-SCCE0625) and
A-Plus Poly(A) Polymerase Tailing Kit (CellScript, C-PAP5104H), respectively, according to the
manufacturer‚Äôs instruction with the following modifications. Aliquots of 30 ¬µg of each RNA were
processed in parallel, diluted to 34.25 ¬µL in water and heated for 5 min at 65¬∞C to denature and
placed on ice. The 50 ¬µL capping reaction contained 5 ¬µL 10x ScriptCap buffer (Cellscript), 5 ¬µL
10 mM GTP (Cellscript), 2.5 ¬µL 2 mM S-adenosyl-methionine (SAM, 20 mM stock, Cellscript),
1.25 ¬µL ScriptGuard RNase Inhibitor (Cellscript), and 2 ¬µL Capping enzyme (20 U, Cellscript, 10
U/¬µL). For the capping step, the 37¬∞C incubation was performed for 1 hour and the capped RNA
was placed on ice. Polyadenylation was performed from the resulting RNAs without purification
in between. The polyA reaction contained 30 ¬µg of capped mRNA in 50 ¬µL, 6.6 ¬µL 10x A-Plus
polyA tailing buffer (Cellscript), 6.6 ¬µL 10 mM ATP (Cellscript), 0.3 ¬µL ScriptGuard RNase
Inhibitor (Cellscript), and 2.5 ¬µL A-Plus PolyA Polymerase (10 U, 4 U/¬µL, Cellscript) in a total
reaction volume of 66 ¬µL. We aimed to add a 150 nt-long polyA-tail for which we incubated the
capped mRNA for 30 min at 37¬∞C with 10 U of polyA enzyme, after which the reaction was
placed on ice. The mRNA was again purified using MegaClear columns. mRNA concentration
was determined on a Nanodrop 2000 (Thermo Fisher). This usually yields 30-40 ¬µg of capped
and polyadenylated mRNA. mRNA quality was determined by

4% urea-PAGE, 1%

formaldehyde agarose gel or capillary electrophoresis with a Agilent 2100 Bioanalyzer (Agilent
Technologies). A list of all primer sequences used are provided in Table S6.
Cell culture and transfection
HEK293T (ATCC: CRL-3216) cells were cultured in Dulbecco‚Äôs Modified Eagle‚Äôs Medium
(DMEM, Gibco, 11965‚Äì118) containing 2 mM L-glutamine, supplemented with 10% fetal bovine
serum (EMD Millipore, TMS-013-B), 100 U/ml penicillin and 0.1 mg/ml streptomycin
(EmbryoMax ES Cell Qualified Penicillin-Streptomycin Solution 100X; EMD Millipore,
TMS-AB2-C or Gibco, 15140‚Äì122) at 37¬∞C in 5% CO2-buffered incubators. For transfection of
pooled 5‚Äô m7G-capped and poly(A)-tailed RNAs, 5.0 x 106 HEK293T cells were seeded in a 10
cm plate 24 h before transfection. 10 ¬µg of pooled RNAs were transfected using Lipofectamine
MessengerMax as per manufacturer‚Äôs instructions (Life Technologies). Media was changed 3 h
after transfection and replaced with complete DMEM supplemented with 10% FBS and

47

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

Pen/Strep. For transfections of individual m7G-capped RNAs, 3.0 x 104 HEK293T cells were
seeded per well 24 h before transfection in a 96-well plate. Subsequently, 10 ng of Nluc RNA
was co-transfected with 20 ng of m7G-capped HBB-Fluc control RNA using Lipofectamine
MessengerMax as per manufacturer‚Äôs instructions (Life Technologies). A list of all primer
sequences used are provided in Table S6. All oligonucleotides were purchased from IDT.
Sucrose gradient fractionation analysis
Cell culture media was replaced with cycloheximide (MilliporeSigma, C7698-1G) containing
media at 100ug/mL. After 2 minutes, cells were washed, trypsinized and harvested using PBS,
trypsin, and culture media containing 100 g/mL cycloheximide. ~10x106 cells were resuspended
in 400 ¬µL of following lysis buffer on ice for 30 min, vortexing every 10 min: 25 mM Tris-HCl pH
7.5, 150 mM NaCl, 15 mM MgCl2, 1 mM DTT, 8% glycerol, 1% Triton X-100, 100 ¬µg/mL
cycloheximide, 0.2 U/¬µL Superase-In RNase inhibitor (ThermoFisher Scientific, AM2694), 1x
Halt protease inhibitor cocktail (ThermoFisher Scientific, 78430), 0.02 U/¬µL TURBO DNase
(ThermoFisher Scientific, AM2238). After lysis, nuclei were removed by two step centrifuging,
first at 1300 g for 5min and second at 10000 g for 5min, taking the supernatants from each.
25%-50% sucrose gradient was prepared in 13.2mL ultracentrifuge tubes (Beckman Coulter,
331372) using Biocomp Gradient Master with the following recipe: 25 or 50% sucrose (w/v),
25 mM Tris-HCl pH 7.5, 150 mM NaCl, 15 mM MgCl2, 1 mM DTT, 100 ¬µg/mL cycloheximide.
The lysate was layered onto the sucrose gradient and ultracentrifuged on Beckman Coulter
SW-41Ti rotor at 40000rpm for 150min at 4¬∞C. The gradient was density fractionated using
Brandel BR-188 into 16x750 ¬µL fractions, and in vitro transcribed spike-in RNA mix (120002B1,
120010B1, 220023B1, 310333T3; 1000, 100, 10, 1-fold dilutions respectively) were added to
each fraction. 700 ¬µL of each fraction was mixed with 100¬µL 10% SDS, 200¬µL 1.5M sodium
acetate, and 900¬µL acid phenol-chloroform, pH 4.5 (ThermoFisher Scientific, AM9720), heated
at 65¬∞C for 5min, and centrifuged at 20000g for 15min at 4¬∞C for phase separation. 600¬µL
aqueous phase was mixed with 600 ¬µL 100% ethanol and RNA was purified on silica columns
(Zymo, R1013).
Luciferase activity assay after mRNA transfection
Media from transiently transfected HEK293T cells was aspirated and cells were lysed in 40 ¬µL
of 1x passive lysis buffer from the Dual-Luciferase Reporter Assay System (Promega, E1980)
and either directly assayed or frozen at -20¬∞C. After thawing, 20 ¬µL of supernatant was
transferred to a new plate and assayed for luciferase activity using the Nano-Glo

48

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

Dual-Luciferase Reporter Assay System (Promega, N1610) to measure Firefly (Fluc) and
NanoLuc (Nluc) luciferase activities. In particular, 50 ¬µL of ONE-Glo Ex Reagent was added to
each well of lysate and incubated for 3 minutes at room temperature before measuring Fluc
activities. Subsequently, 50 ¬µL of NanoDLR Stop & Glo reagent was added to each well, and
incubated for 10 min at room temperature before measuring luciferase activities on a
GloMax-Multi (Promega) plate reader. Luciferase reporter activity is expressed as a ratio
between Nluc and Fluc. Each experiment was performed a minimum of three independent
times. Because this assay relies on accumulation of luciferase in the cytosol, any signal
peptides sequences (Table S1) were removed from the CDS for templates and mRNA for these
transfection and luciferase activity experiments .
Quantitative RT-PCR (RT-qPCR) Analysis
RNA-transfected HEK293T cells were first lysed and separated by sucrose density gradient
fractionation as described above. From each fraction. RNA was purified by acidic
phenol/chloroform followed by isopropanol precipitation. 0.5 mg of RNA was converted to cDNA
using iScript Supermix (Bio-Rad, 1708840). cDNA was synthesized from 100-200 ng of total
RNA using iScript Supermix (Bio-Rad, 1708840) containing random hexamer primers, according
to the manufacturer‚Äôs instructions. PCR reactions were assembled in 384-well plates using 2.5
¬µL of a 1:4-1:5 dilution of a cDNA reaction, 300 nM of target-specific primer mix and the
SsoAdvanced SYBR Green supermix (Bio-Rad, 1725270) in a final volume of 10 ¬µL per well.
Data were analysed and converted to relative RNA quantity using CFX manager (BioRad). For
sucrose gradient fractions, the amount of RNA from individual fractions was expressed as a
fraction of the total RNA collected from all fractions. Primers were used at 250 nM per reaction.
A list of all primer sequences used for qPCR are provided in Table S6.
In cell and in-solution RNA degradation time courses
For in-cell RNA stability, the 233-member in vitro transcribed mRNA pool (m7G-capped and
polyA) was transfected into HEK293T cells as described above and RNA was harvested at 1, 7,
12, and 24 h in Trizol (ThermoFisher Scientific, 15596026). RNA was extracted from the
aqueous phase on silica columns (Zymo, R1013).
For in-solution RNA degradation experiments, 750 ng of the 233-mRNA pool (not
m7G-capped or polyA) was incubated in 30 ¬µL of Degradation Buffer (50 mM CHES at pH 10
and 10 mM MgCl2) and collected over 10 time points: 0, 0.5, 1, 2, 3, 4, 5, 6, 16 and 24 h. To
each sample, 15 ¬µL of 0.5 M Tris-HCl pH 7 and 3 ¬µL of 0.5 M EDTA-Na was added to quench
the degradation. The integrity of each sample was checked by loading 5 ¬µL of total RNA
49

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

alongside a spike-in control (P4P62HP, 50 ng) onto a PAGE-Urea-TBE gel and visualized by
SYBR Gold (Thermo Fisher). Subsequently, RNA was purified using Ampure beads + 40%
polyethylene glycol 8000 (7:3) and checked again by PAGE-Urea-TBE gel and visualized by
SYBR Gold.
Library preparation and amplicon Sequencing
Up to 250 ng RNA in 2.75 ¬µL was mixed with 0.25 ¬µL 2 ¬µM RT_Const2_N12_Read1Partial
(Table S6) and 0.25 ¬µL 10mM dNTPs each. The RNA samples were then denatured at 65¬∞C for
5 min and chilled to 4¬∞C. 1.75 ¬µL reverse transcription mix was added to 5 ¬µL total reaction
volume: 1 ¬µL 5x Superscript IV buffer, 0.25 ¬µL 10mM DTT, 0.25 ¬µL Superase-In (ThermoFisher
Scientific, AM2694), 0.25 ¬µL Superscript IV (Thermo 18091050). The reaction was incubated at
55¬∞C for 45 min and inactivated at 80¬∞C for 10 min.
First round PCR was performed under following conditions: 1 ¬µL RT reaction, 10 ¬µL 2x
Q5 Hot Start Master Mix (NEB M0494S), 0.2 ¬µL 100x SYBR (Thermo S7563), 1 ¬µL 10uM
Read1Partial_F, 1 ¬µL 10 uM 50:50 Hbb_Fwd:Nluc_Fwd mix in 20 ¬µL total volume. Cycling
conditions were: 98¬∞C for 60 sec, and 15 cycles of 98¬∞C for 10 sec, 68¬∞C for 10 sec and 72¬∞C.
Second round PCR was performed under the following conditions: 1 ¬µL first round PCR, 10 ¬µL
2x Q5 Hot Start Master Mix, 0.2 ¬µL 100x SYBR, 1 ¬µL 10 uM Read1Partial_F, 1 ¬µL 10 uM
Read2Partial_Const1_R in 20 ¬µL total volume. Cycling conditions were: 98¬∞C for 60 sec, and 5
cycles of 98¬∞C for 10 sec, 72¬∞C for 5 sec. Sequencing adaptors were added using the following
conditions for final round PCR: 1 ¬µL second round PCR, 10 ¬µL 2x Q5 Hot Start Master Mix, 0.2
¬µL 100x SYBR, 1 ¬µL 10 ¬µM NEBNext Index Primer (NEB E7335, NEB E7500, NEB E7710, NEB
E7730, NEB E6609), 1 ¬µL 10 ¬µM NEBNext Universal PCR Primer in 20 ¬µL total volume. Cycling
conditions were: 98¬∞C for 60 sec, and 5 cycles of 98¬∞C for 10 sec, 72¬∞C for 5 sec. All barcoded
samples were then pooled at equal volumes and purified with 1.1x SPRIselect beads (Beckman
Coulter B23317). Sequencing was performed at the Stanford Functional Genomics Facility
(SFGF) at Stanford University, on an Illumina NextSeq 550 instrument, using a high output kit,
1x76 cycles. Primer sequences and the sequencing construct layout are provided in Table S6.
Amplicon sequencing data analysis
After bcl conversion and demultiplexing with Illumina bcl2fastq, the constant regions were
trimmed using cutadapt88. The trimmed reads were aligned to the indexed reference of barcode
sequences using Bowtie2 with the following options: -L 11 -N 0 --nofw

89

. The alignments were

deduplicated based on UMIs using UMIcollapse90 with -p 0.05 and counted using samtools

50

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

idxstats. This pipeline yields a matrix of barcode read counts where rows are the different
constructs in the library and columns are the different samples.
The count matrix was log transformed and normalized column-wise using a linear fit on
the dilution series of spike-in constructs in each sample. For the calculation of RNA degradation
coefficients in cells, we carried out a linear fit to log RNA abundance from the time course data,
i.e. we fit an expression of Y = Œ≤0+Œ≤1t where Y is the normalized log RNA abundance and t is the
number of hours after transfection; Œ≤1 is the degradation constant. For the calculation of in
solution degradation coefficients, sufficient data points were available to carry out a nonlinear fit
directly to an exponential model, i.e. we fit an expression of y = A exp(-ùõï/t), where y is the
fraction intact (RNA abundance normalized to initial abundance), A is the amplitude, t is the time
of incubation in degradation buffer in hours, and ùõï is the degradation time constant.
For polysome profiles, percent RNA abundances for each fraction were first calculated
by scaling per-fraction values by the sum of all fractions. For the heatmap displays in the
figures, column medians were also subtracted from each percent RNA value. For the calculation
of ribosome load, the matrix of percent RNA abundances in fractions 4-9 (1-3 are free RNP
fractions, and >9 have negligible abundance) were first multiplied by a weight vector
representing the number of ribosomes in each fraction as determined by the A260 trace from
the fractionator, then the weighted abundances were summed across the row. For the
calculation of polysome to monosome ratio, the sum of fractions 7-9 (>3 ribosomes)
abundances were divided by fraction 4 (80S) abundance. For the calculation of monosome to
40S/60S ratio, fraction 4 (80S) abundance was divided by the sum of fraction 2 (40S/60S)
abundance.
To calculated the expected protein levels assuming first order kinetics of mRNA
translation and mRNA/protein decay, the following differential equations are used:
ùëëùëÄ
ùëëùë°
ùëëùëÉ
ùëëùë°

=

‚àí ùëòùëö ¬∑ ùëÄ(ùë°)

= ùëòùë° ¬∑ ùëÄ(ùë°) ‚àí ùëòùëù ¬∑ ùëÉ(ùë°).

where dM/dt and dP/dt are rates of change in mRNA and protein levels, respectively; M(t) and
P(t) are moles of mRNA and protein at time t, respectively; kt is the translation rate constant;
and km and kp are rate constants of mRNA and protein decay, respectively. The analytical
solution for P(t) is proportional to:

51

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

‚àíùëòùëùùë°

ùëÉ(ùë°) ‚àº ùëòùë°

ùëí

‚àíùëò ùë°

‚àíùëí ùëö
ùëòùëö‚àíùëòùëù

.

where m0 is the mass of mRNA present at t=0, and l is the mRNA length in nucleotides. kp is set
to 0 since Nluc protein has negligible degradation as measured by luciferase activity in
transiently Nluc-expressing HEK293 cells for at least 6 hours after cycloheximide treatment,
which allows assessment of protein degradation in the absence of further translation91. km is the
degradation constant obtained from the linear fit of in-cell time course RNA data (‚ÄìŒ≤1 above). kt
is the ribosome load calculated by summing weighted RNA abundances from polysome profile
data.
SHAPE and DMS chemical mapping of full-length mRNAs
For DMS-based chemical mapping of the LinearDesign-1 and Yellowstone mRNAs, 1 ¬µg of RNA
was brought to 10 ¬µL in water, unfolded at 95 ¬∞C for 2 minutes, then snap-cooled on ice for 1
minute. The RNA was then mixed with 25 ¬µL water and 10 ¬µL 5X folding buffer (1.5 M sodium
cacodylate pH 7.0, 50 mM MgCl2) and folded at 37 ¬∞C for 30 minutes. The folded RNA was
modified by adding 5 ¬µL of 15% dimethyl sulfate (v/v in ethanol) or water (negative control).
Both reactions were incubated at 37 ¬∞C for 6 minutes, quenched by the addition of 50 ¬µL
beta-mercaptoethanol, purified using the Zymo RNA Clean and Concentrator 5 kit (Zymo
Research), and eluted in 12 ¬µL water. For reverse transcription, 10 ¬µL of the modified RNA was
mixed with 1 ¬µL of 10 ¬µM oVT555, incubated at 65 ¬∞C for 5 min, and snap cooled on ice. Then,
the template-primer mix was combined with 4 ¬µL of 5X TGIRT First Strand Synthesis Buffer
(250 mM Tris-HCl pH 8.3, 375 mM KCl, 15 mM MgCl2), 2 ¬µL 10 mM dNTPs, 1 ¬µL freshly
prepared 100 mM DTT, and 0.5 ¬µL TGIRT-III (InGex LLC). The reaction was mixed and
incubated at 57 ¬∞C for 3 hours. RNA was then hydrolyzed by addition of 10 ¬µL hydrolysis buffer
(0.5 M NaOH, 0.25 M EDTA) and incubation at 65 ¬∞C for 15 min. Hydrolysis was quenched by
bringing the reaction volume to 50 ¬µL with water, adding 100 ¬µL of Oligo Binding Buffer (Zymo
Research), and proceeding through the Zymo Oligo Clean and Concentrator (Zymo Research)
purification protocol, eluting in 15 ¬µL of water. 5 ¬µL of the purified cDNA was amplified in a
NEBNext Q5 HotStart master mix PCR reaction containing 0.5 ¬µM each oVT554 and oVT555
with the following cycling conditions: 98 ¬∞C for 30 seconds, 10 cycles of 98 ¬∞C for 10 seconds
followed by 72 ¬∞C for 60 seconds, with a final extension of 72 ¬∞C for 5 minutes. Products were
purified using 0.9X Select-a-Size DNA Clean and Concentrator MagBeads (Zymo Research).

52

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

Amplification of the full-length cDNA product was verified on an agarose gel stained with
SYBRSafe (Invitrogen).
For SHAPE-based chemical mapping, 500 ng of RNA was brought to 12 ¬µL in water and
denatured at 95¬∞C for 2 minutes followed by snap-cooling on ice for 2 minutes. The RNA was
then folded by adding 6 ¬µL of 3.3X SHAPE folding buffer (333 mM HEPES pH 8.0, 333 mM
NaCl, 33 mM MgCl2) and incubating at 37¬∞C for 20 minutes. 9 ¬µL of the folded RNA was mixed
with 1 ¬µL of either 100 mM 1M7 (1-Methyl-7-nitroisatoic anhydride, freshly mixed in DMSO) or
neat DMSO (negative control), mixed thoroughly by pipetting, and incubated at 37¬∞C for 75
seconds (roughly 5 1M7 hydrolysis half-lives). After chemical treatment, the volume of both
reactions was brought to 50 ¬µL with water, cleaned up with the Zymo RNA Clean and
Concentrator 5 kit, and eluted in 12 ¬µL of water. 10 ¬µL of eluted RNA was mixed with 1 ¬µL of
200 ng/¬µL random nonamer primer (New England Biolabs), incubated at 65¬∞C for 5 minutes,
then snap-cooled on ice. Then, 8 ¬µL of 2.5X MaP buffer (125 mM Tris pH 8.0, 187.5 mM KCl, 25
mM DTT, 1.25 mM each dNTPs, 15 mM MnCl2), was added to the primer-template mixture,
incubated at room temperature for 2 minutes, and then mixed with 1 ¬µL of SuperScript II
(Invitrogen). The reverse transcription reaction was thoroughly mixed by pipetting, incubated at
room temperature for 10 minutes, then at 42 ¬∞C for 3 hours. The reverse transcription enzyme
was heat inactivated at 70¬∞C for 15 min, snap-cooled on ice, then immediately mixed with 8 ¬µL
NEBNext Second Strand Synthesis Reaction Buffer (New England Biolabs), 4 ¬µL NEBNext
Second Strand Synthesis Enzyme Mix (New England Biolabs), and 48 ¬µL water. The second
strand synthesis reaction was mixed thoroughly through pipetting and incubated in a
thermocycler with the heated lid off at 16¬∞C for 60 min. The resulting double-stranded cDNA
was purified with 1.8X volumes of Select-a-Size DNA Clean and Concentrator MagBeads (Zymo
Research).
Double-stranded cDNA was prepared for Illumina sequencing with the NEBNext Ultra II
FS DNA Library Prep Kit for Illumina (New England Biolabs) and iTru primers. Briefly,
100-500ng of DNA from either 1M7 or DMS conditions in 26 ¬µL of water was fragmented and
end-repaired by adding 7 ¬µL NEBNext Ultra II FS Reaction Buffer and 2 ¬µL NEBNext Ultra II FS
Enzyme Mix, mixed thoroughly by vortexing, and incubated in a thermocycler with heated lid on
at 37¬∞C for 20 min, then 65¬∞C for 20 min. Fresh ligation adapter was prepared by denaturing a
solution of 15 ¬µM each of iTrusR1-stub and iTrusR2-stubRCp in salty TLE (10 mM Tris pH 8.0,
0.1 mM EDTA, 100 mM NaCl) at 95¬∞C for 1 minute, then annealed via slow cooling at -0.1¬∞C/s
to 25¬∞C. The fragmented and end-repaired DNA was mixed with 2.5 ¬µL 15 ¬µM ligation adapter,
30 ¬µL NEBNext Ultra II FS Ligation Master Mix, and 1 ¬µL NEBNext Ultra II FS Ligation

53

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

Enhancer. The ligation reaction was incubated in a thermocycler (heated lid off) at 20¬∞C for 60
min. Ligated fragments were purified with 0.9X Select-a-Size DNA Clean and Concentrator
MagBeads (Zymo Research) and eluted in 25 ¬µL water. Dual-index sample barcodes were
added through indexing PCR using the NEBNext Q5 Hot Start HiFi PCR Master Mix in a
reaction with 0.5 ¬µM each of iTru_5 and iTru_7 indexing primers with the following
thermocycling parameters: 98¬∞C for 30 s, 8 cycles of 98¬∞C for 10 s, 55¬∞C for 10 s, 72¬∞C for 15 s,
and a final extension at 72¬∞C for 5 min. The final sequencing libraries were purified with 0.9X
volumes of Select-a-Size DNA Clean and Concentrator MagBeads (Zymo Research), quantified
by qPCR using the iTaq Universal SYBR Green Supermix (Bio-Rad) with iTru_P5 and iTru_P7
primers, pooled in equimolar concentrations, and sequenced on an Illumina Miseq (Stanford
Protein and Nucleic Acid Core Facility) for 600 cycles.
Demultiplexed reads were downloaded from the BaseSpace Sequence Hub (Illumina).
Most analysis steps were carried out using the RNAFramework RNA structure probing analysis
toolkit92. Using the `rf-map` module, reads were trimmed with CutAdapt88 and mapped to the
wild-type RNA sequence using Bowtie 289. Mutations were counted using the `rf-count` module
with `-m` flag, then normalized using the `rf-norm` module with `-sm 4 -nm 2 -rb AC -nw 50 -dw`
flags for DMS samples and `-sm 3 -nm 2 -rb N -nw 50 -dw` flags for 1M7 samples. These
normalized reactivities (Table S4) were plotted as-is, and also used to predict RNA secondary
structure

using

the

RNAStructure93

`Fold`

command,

implemented

in

Arnie

(https://github.com/DasLab/arnie).
High-throughput in-line and SHAPE probing on Eterna-designed RNA fragments
(In-line-seq)
The In-line-seq experiments relied on a different pipeline for massively parallel RNA generation,
treatment, and Illumina sequencing than mRNA experiments above. We describe these steps
below; see ref.94 for further details and Table S6 for primers.
Preparation of DNA templates
DNA

fragments

encoding

for

RNA

molecules

from

the

Eterna

‚ÄòOpenVaccine:

Roll-your-own-structure‚Äô challenge were ordered in the form of a custom oligonucleotide pool of
DNA (Custom Array/Genscript) with the 20-nt T7 RNA polymerase promoter sequence
(5‚Äô-TTCTAATACGACTCACTATA-3‚Äô) prepended to each DNA. Amplification of the DNA template
was performed via emulsion PCR. A hydrophobic solution (‚Äòoil phase‚Äô) containing 80 ¬µL of ABIL
EM90 (Evonik Corporation), 1 ¬µL of Triton X-100, and 1919 ¬µL of mineral oil was vortexed for 5
minutes and then incubated on ice for 30 minutes. Then, 75 ¬µL of water-soluble reaction mixture

54

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

(liquid phase) containing 1X Phire Hot Start II buffer, 0.2 mM dNTPs, 1.5 ¬µL of Phire II DNA
polymerase, 2 ¬µM of each primer (T7 promoter and Tail2 Reverse complement), 0.5 mg/ml of
BSA, and 360 ng of the oligonucleotide pool was prepared. In a 1.0 ml glass vial (kept on ice
and frozen at -20¬∞C overnight before use), 300 ¬µL of the oil phase was added into the glass vial
and vortexed at 1000 rpm for 5 minutes. Next, 10 ¬µL of the liquid phase was added followed by
10 seconds of vortexing. This addition of the liquid phase followed by vortexing was repeated 4
times such that 50 ¬µL of the liquid phase has been added to 300 ¬µL of the oil phase in the vial.
The now-mixed 350 ¬µL of emulsion PCR solution was the subjected to the following
thermocycling protocol: 98¬∞C for 30 seconds for initial denaturation, 42 cycles of amplification
(98¬∞C for 10 seconds, 55¬∞C for 10 seconds, and 72¬∞C for 30 seconds), and final extension at
72¬∞C for 5 minutes
The PCR was purified by adding 100 ¬µL of mineral oil, followed by a brief vortex (~10
seconds) and centrifugation at 13,000 rcf for 10 minutes. The oil phase was then discarded. 1
mL of diethyl ether was added, followed by a brief vortex (~10 seconds) and centrifugation at
13,000 rcf for 1 minute. The upper layer (termed the detergent layer) was then discarded.
Extraction with diethyl ether was repeated 3 times to ensure through purification. The resulting
product was then incubated at 37¬∞C for 5 minutes, adjusted to a final volume of 40 ¬µL with
nuclease-free water, then purified with 72 ¬µL of Ampure bead XP (Beckman Coulter) following
the standard protocol specified by the vendor. Finally, DNA was eluted into 20 ¬µL of
nuclease-free water.
Preparation of RNA templates
A library of RNA molecules was then prepared from the amplified DNA template using the
TranscriptAid T7 High Yield Transcription Kit (Thermofisher, K0441) using the reaction mixture
specified by the vendor. Transcription was performed with incubation at 37¬∞C for 3 hours. After
transcription, the DNA template was removed through the addition of 2 ¬µL of DNAse I (add
vendor) followed by incubation at 37¬∞C for 30 minutes. After DNA digestion, the RNA was
purified using a mixture of AMPure XP beads (Beckman Coulter) with 40% polyethylene glycol
(mixed in a 7:3 ratio). Final elution into 25 ¬µL of nuclease-free water yielded purified RNA.
Degradation in-line probing of RNA samples
For degradation experiments, 45-50 pmol of RNA was subject to four conditions: 1) 50 mM
Na-CHES buffer (pH 10.0) at room temperature without added MgCl2; 2) 50 mM Na-CHES
buffer (pH 10.0) at room temperature with 10 mM MgCl2; 3) phosphate buffered saline (PBS, pH

55

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

7.2; Thermo Fisher Scientific-Gibco 20012027) at 50¬∞C without added MgCl2 ; and 4) PBS (pH
7.2) at 50¬∞C with 10 mM MgCl2.
For degradation reactions containing MgCl2, RNA was collected at 0 and 24 hour time
points. For reactions without MgCl2, timepoints were collected at 0 and 7 days. At each
timepoint, the degradation reaction was quenched with 15 ¬µL of 500 mM of Tris-HCl (pH 7) and
3 ¬µL of 500 mM of Na-EDTA. Quenched samples were brought to a final volume of 100 ¬µL with
nuclease-free water. The RNA was purified through precipitation as follows. 1.5 ¬µL of Glyco
Blue (Thermo Fisher), 10 ¬µL of 3 M sodium acetate (pH 5.2), and 330 ¬µL of cold 100 % ethanol
were added, the reaction mixture mixed, and incubated on dry ice for 20 to 30 minutes. After
incubation, the reaction was centrifuged at 21,000 rcf for 30 minutes. The resulting pellet was
washed twice with 500 ¬µL of cold 70% ethanol, and pelleted after each wash step. Finally, the
reaction was dried for 10 minute at room temperature to remove any residual ethanol, and
resuspended in 5 ¬µL of nuclease-free water.
Structure probing of RNA samples
In parallel with the in-line hydrolytic degradation conditions above, we carried out SHAPE
structure probing experiments64, as follows. 15 pmol of purified RNA was added to 2 ¬µL of 500
mM HEPES buffer (pH 8.0) and denatured at 90¬∞C for 3 minutes. The reaction was then cooled
down to room temperature over 10 minutes. 2 ¬µL of 100 mM MgCl2 was then added, followed by
incubation at 50¬∞C for 30 minutes. The sample was cooled down to room temperature over 20
minutes before addition of 5 ¬µL of 1-methyl-7-nitroisatoic anhydride (1M7, 8.48 mg/mL of
DMSO) followed by incubation at room temperature for 15 min, and brought to a final volume of
20 ¬µL with nuclease-free water. The reaction was quenched with 5 ¬µL of 500 mM Na-MES pH
6.0, the reaction was adjusted to be 100 ¬µL, and purified with ethanol precipitation as above. As
a control, a sample was prepared in parallel without addition of 1M7 but subject to the same
protocol described above.
Preparation of cDNA and sequencing
cDNA was prepared from the six RNA samples (two from structure probing, four from
degradation). 5 ¬µL of purified RNA was added to a reaction mixture containing 1x First Strand
buffer (Thermo Fisher), 5 mM dithiothreitol (DTT), 0.8 mM dNTPs, 0.6 ¬µL of SuperScript III
RTase (Thermo Fisher) to a final volume of 15 ¬µL. The reaction was incubated at 48 ¬∞C for 40
minutes and stopped with 5 ¬µL of 0.4 M sodium hydroxide. The reaction was then incubated at
90 C for 3 minutes, cooled on ice for 3 minutes, and neutralized with 2 ¬µL of quench mix

56

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

(prepared as 2 mL of 5 M sodium chloride, 3 mL of 3 M sodium acetate, 2 mL of 2 M
hydrochloric acid).
cDNA was pooled down with 1.5 uL of Oligo C‚Äô beads64 (in house magnetic beads
prepared by immobilizing 2x Biotin oligonucleotides with Dynabeads‚Ñ¢ MyOne‚Ñ¢ Streptavidin
C1; Thermo Fisher Scientific 65001), washed twice with 70% ethanol, then resuspended in 3.0
¬µL of water. We pooled 1.5 ¬µL of each sample together, and took 9 ¬µL of cDNA to continue to
ligation an Illumina adapter by using Circ. Ligase I (Lucigen) at 68¬∞C for 2 h. The reaction was
stopped by incubation at 80 ¬∞C for 10 min. cDNA was added to 10 ul of 5 M NaCl and pulled
down with a magnetic stand and washed with 70% ethanol; the ligated product was
resuspended in 15 ¬µL H 2O.
Ligated product was quantified by qPCR. dsDNA at 3 nM concentration was sequenced
using an Illumina Miseq (High output, Read 1 = 101 cycles and Read 2 = 51 cycles). The
resulting data were analyzed using MAPseeker (https://ribokit.github.io/MAPseeker)95 following
the recommended steps for sequence assignment, peak fitting, background subtraction of the
no-modification control, correction for signal attenuation, and reactivity profile normalization.
In-line and SHAPE probing by capillary electrophoresis
One-by-one followup to profile degradation of RNA fragments at single-nucleotide resolution
through capillary electrophoresis was carried out with some differences to the pooled In-line-seq
experiments above. We describe these steps below; see ref.94 for further details and Table S6
for primers.
DNA template preparation
DNA templates were designed to include the 20-nt T7 RNA polymerase promoter sequence
(5‚Äô-TTCTAATACGACTCACTATA-3‚Äô) followed by the remaining sequence encoding desired
RNA. Double-stranded templates were prepared by extension of 60-nt DNA oligomers (IDT,
Integrated DNA Technologies) with Phusion DNA polymerase (Finnzymes), using the following
thermocycler protocol: denaturation for 30 sec at 98¬∞C, 35 cycles of denaturation for 10 sec at
98¬∞C annealing for 30 sec at 60 to 64¬∞C , extension for 30 sec at 72¬∞C; final extension for 10
min at 72 ¬∞C and cooling to 4¬∞C.
DNA samples were purified with AMPure magnetic beads (Agencourt, Beckman Coulter)
following manufacturer‚Äôs instructions. Sample concentrations were estimated based on UV
absorbance at 260 nm measured on Nanodrop 100 or 8000 spectrophotometers. Verification of
template length was accomplished by electrophoresis of all samples and 10-bp and 20-bp
ladder length standards (Thermo Scientific O'RangeRuler SM1313 & SM1323) in 4% agarose

57

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

gels (containing 0.5 mg/mL ethidium bromide) and 1x TBE (100 mM Tris, 83 mM boric acid, 1
mM disodium EDTA). All sample manipulations, including following steps, were carried out in
96-well V-shaped polypropylene microplates (Greiner).
Preparation of RNA templates
In vitro transcription reactions were carried out in 40 ¬µL volumes with 10 pmol of DNA template,
using the TranscriptAid T7 High Yield Transcription Kit (Thermo Fisher, K0441). In some
syntheses,

pseudouridine-5'-triphosphate

(TriLink

Biotechnologies,

N-1019)

or

N1-methylpseudouridine-5'-triphosphate (TriLink Biotechnologies, N-1081) were used to replace
regular UTP. Reactions were incubated for 3 hours at 37¬∞C, followed by degradation of DNA
template with 2 ¬µL of DNase I at 37¬∞C for 30 min. RNA samples were purified with 1.8x volume
of AMPure XP beads (Beckman Coulter) mixed with 40% PEG-8000 (ratio of 7:3), following
manufacturer‚Äôs instructions. Concentrations were measured by absorbance at 260 nm on
Nanodrop 100 or 8000 spectrophotometers.
In-line probing (hydrolytic degradation profiling)
For degradation experiments, 750 ng of RNA was subjected to 50 mM Na-CHES buffer (pH 10)
at room temperature with 10 mM MgCl2 at a final volume of 30 ¬µL. RNA was collected at 0- and
24-hour time points. At each timepoint, 15 ¬µL of reaction was taken, and degradation quenched
with 7.5 ¬µL of 500 mM of Tris-HCl (pH 7) and 1.5 ¬µL of 500 mM of Na-EDTA. Quenched
samples were purified with 2 ¬µL of Oligo dT bead (Thermo Fisher, AM1922) and 0.8 ¬µL of
10 ¬µM FAM-A20-Tail2. RNA, bead, and primer were incubated at room temperature for 15 min,
pulled down by magnetic stand for 10 min, and washed twice with 70% ethanol and left to dry
on the bead. RNA was eluted in 2.5 ¬µL of nuclease-free water (RNA was binded with OligodT
bead and FAM.A20 Tail2 at this point). Subsequently, these RNAs were further treated and
purified with steps analogous to SHAPE probing (see next) to enable side-by-side comparisons.
RNAs were added to 2 ¬µL of 500 mM Na-HEPES buffer (pH 8.0) and denatured at 90¬∞C for 3
minutes. The reaction was then cooled down to room temperature over 10 minutes. 2 ¬µL of 100
mM MgCl2 was then added, followed by incubation at 50¬∞C for 30 minutes. The sample was
cooled down to room temperature over 20 minutes before addition of 5 ¬µL of nuclease-free
water, followed by incubation at room temperature for 15 min, and brought to a final volume of
20 ¬µL with nuclease-free water. The RNA sample was further purified by incubating the sample
with 5.0 ¬µL of Na-MES, pH 6.0, 3.0 ¬µL of 5 M NaCl, and brought to a final volume of 10 ¬µL with
nuclease-free water. The reaction mixture was incubated at room temp for 15 min, pulled down

58

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

by 96-post magnetic stand for 10 min, washed twice with 70% ethanol and allowed to dry,
before adding 2.5 ¬µL of nuclease-free water.
SHAPE experiments
For SHAPE structure probing experiments, 1.2 pmol of purified RNA was added to 2 ¬µL of 500
mM Na- HEPES buffer (pH 8.0) and denatured at 90¬∞C for 3 minutes. The reaction was then
cooled down to room temperature over 10 minutes. 2 ¬µL of 100 mM MgCl2 was then added,
followed by incubation at 50¬∞C for 30 minutes. The sample was cooled down to room
temperature over 20 minutes before addition of 5 ¬µL of nuclease-free water (negative control) or
1-methyl-7-nitroisatoic anhydride (1M7, 8.48 mg/mL of DMSO) followed by incubation at room
temperature for 15 min, and brought to a final volume of 20 ¬µL with nuclease-free water. The
SHAPE-RNA sample was further purified by incubating the sample with 5.0 ¬µL of Na-MES, pH
6.0, 3.0 ¬µL of 5 M NaCl, 1.5 ¬µL of Oligo dT bead, 0.25 ¬µL of 10 ¬µM FAM-A20-Tail2, and brought
to a final volume of 10 ¬µL with nuclease-free water. The reaction mixture was incubated at room
temp for 15 min, pulled down by 96-post magnetic stand for 10 min, washed twice with 70%
ethanol and allowed to dry, before adding 2.5 ¬µL of nuclease-free water.
Preparation of in-line probing and SHAPE samples for capillary electrophoresis
cDNA was prepared from in-line probing and SHAPE RNA samples as follows (note that
above procedures leave RNA bound to FAM-A20-Tail2 reverse transcription primers which are
in turn bound to Oligo dT beads). 2.5 ¬µL of purified RNA was added to a reaction mixture
containing 1x First Strand buffer (Thermo Fisher), 5 mM dithiothreitol (DTT), 0.8 mM dNTPs, 0.2
¬µL of SS-III RTase (Thermo Fisher) to a final volume of 5.0 ¬µL. The reaction was incubated at
48ÀöC for 40 minutes, and stopped with 5 ¬µL of 0.4 M sodium hydroxide. The reaction was then
incubated at 90ÀöC for 3 minutes, cooled on ice for 3 minutes, and neutralized with 2 ¬µL of
quench mix (2 mL of 5 M sodium chloride, 3 mL of 3 M sodium acetate, 2 mL of 2 M
hydrochloric acid). For four cDNA reference ladders, each of four ddNTPs (GE Healthcare
27-2045-01) with a ddNTP/dNTP ratio of 1.25 (0.1 mM / 0.08 mM) was used in the
reverse-transcription reaction.
cDNA was pulled down on a 96-post magnetic stand and washed 2 times with 100 ŒºL
70% ethanol. To elute the bound cDNA, the magnetic beads were resuspended in 10.0625 ŒºL
ROX350 (Thermo Fisher Scientific 401735) /Hi-Di (0.0625 ŒºL of ROX 350 ladder in 10 ŒºL of
Hi-Di formamide) and incubated at room temperature for 20 minutes. The cDNA was further
diluted by 1/3 and 1/10 in ROX350/HiDi and samples loaded onto capillary electrophoresis

59

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

sequencers (ABI-3730) on capillary electrophoresis (CE) services rendered by ELIM
Biopharmaceuticals.

CE

data

was

(https://github.com/ribokit/HiTRACE),

analyzed

following

the

using

the

HiTRACE

recommended

steps

2.0

package96

for

sequence

assignment, peak fitting, background subtraction of the no-modification control, correction for
signal attenuation, and reactivity profile normalization.
Measurement of in-solution mRNA stability by capillary electrophoresis
For one-by-one measurement of in-solution mRNA stability, in vitro transcribed mRNA was
incubated in a degradation buffer over ten time points (0, 0.5, 1.0, 1.5, 2, 3, 4, 5, 18, and 24
hours), then analyzed by capillary electrophoresis.
For each time point, 1.6 pmol of mRNA brought to 10 ŒºL in a buffer containing 50 mM
Na-CHES at pH 10 with 10 mM MgCl2, and the reaction was incubated at 25 ¬∞C. When the
incubation period was reached for each time point, 5 ŒºL of Tris-HCl at pH 7 and 1 ŒºL of 500 mM
EDTA in nuclease free water was added to quench the degradation reaction, and frozen for
further analysis. After the final time point (24 hours), 4 ŒºL of each mRNA degradation sample
(out of a total stored volume of 16 ŒºL) was taken, and mixed with 1 ŒºL of a control RNA at a
concentration of 50 ng/ŒºL. For these experiments we opted to use the P4-P6 domain of the
Tetrahymena ribozyme with two added hairpins94 (~239 nt) as our control. The RNA mixture was
then purified using a mixture of AMPure XP beads (Beckman Coulter) with 40% polyethylene
glycol (mixed in a 7:3 ratio). The resulting RNA was eluted into 4.5 ŒºL of RNAse-free water for
analysis on the 2100 Bioanalyzer (Agilent) using the RNA-Nano Eukaryote protocol.
The data from the Bioanalyzer were analyzed using a custom script that performs the
following analysis. We first converted elution times to nucleotides based on a ladder control (25,
200, 500, 1000, 2000, and 4000 nts). We then estimated relative mRNA amounts based on
peak areas at expected band lengths (in our case, ~900 nucleotides for the mRNAs of interest
and ~265 nucleotides for the control). When calculating peak areas, we performed background
subtraction, where the background was defined as the area under a linear line in the range of
nucleotides used for the peak area. Normalization was performed using two different methods
used to cross-validate. First, we normalized the peak areas of full-length mRNA to the control
P4-P6 domain RNA that was spiked into the samples after degradation was performed. Second,
we also normalized peak areas of full-length mRNAs to the total amount of RNA in the lane less
the peak area of the bands of interest (between ~20-1000 nucleotides in our case), assuming
that the majority of the other RNA in the lane were degradation products from the mRNA of
interest. These distinct approaches to normalizing the data gave the same results within

60

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

estimated error (see below). After calculations of normalized peak areas, we then calculated
fraction intact values for each mRNA by dividing the normalized area across the ten timepoints
by the normalized area at the start (0 hours).

ùêπùëüùëéùëêùë°ùëñùëúùëõ ùêºùëõùë°ùëéùëêùë°ùëñ =

ùëÅùëúùëüùëöùëéùëôùëñùëßùëíùëë ùê¥ùëüùëíùëéùëñ
ùëÅùëúùëüùëöùëéùëôùëñùëßùëíùëë ùê¥ùëüùëíùëé0 ‚Ñéùëúùë¢ùëüùë†

For each sample, we fit fraction intact values across the different timepoints to an exponential
function,
‚àíœÑ/ùë°

ùêπùëñ = ùê¥ùëí

Where Fi is an array of fraction intact values across multiple time points, A is the amplitude of
the exponential decay function, ùúè is the time constant, and t is an array of time points in hours.
We then used the time constant to calculate the in vitro half-life of mRNA:

ùêªùëéùëôùëì ‚àí ùëôùëñùëìùëí = ùëôùëõ(2) œÑ
Polysome selection and library preparation
The variant 5‚Äô UTR is composed of: fixed first 29 nt of hHBB, variable 35 nt (initially degenerate)
and 6 nt Kozak consensus. See Table S6 for the detailed construct layout. To generate the
reporter mRNA pool containing the variant 5‚Äô UTR library, IVT template was first assembled by
PCR under the following conditions: 4 ¬µL 10x AccuPrime Pfx Reaction Mix, 0.4 pmol
HBB29_N35 amplicon, 0.4 pmol Nluc_HBB_3UTR, 0.4 ¬µL AccuPrime Pfx Polymerase in 40 ¬µL
of total reaction volume. Cycling conditions are: 95¬∞C for 120 sec, and 19 cycles of 95¬∞C for 15
sec, 66¬∞C for 30 sec, 68¬∞C for 75 sec. PCR product was purified on silica columns (NEB T1034)
and amplified with under the following conditions: 4 uL 10X AccuPrime Pfx Reaction Mix, 4 ¬µL
10 ¬µM T7_28_HBB_30_F, 4 ¬µL 10 ¬µM Nanoluc_ORF_R, 0.4 ¬µL AccuPrime Pfx Polymerase in
40 ¬µL total reaction volume. Cycling conditions are: 95¬∞C for 120 sec, and 4 cycles of 95¬∞C for
15 sec, 66¬∞C for 30 sec, 68¬∞C for 75 sec. The mRNA was in vitro transcribed, capped and
polyadenylated as described above.

61

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

Transfection of HEK-293 cells and sucrose gradient fractionation were performed as
described above. Equal volumes of fractions 10-16 were pooled and RNA was by acidic phenol
chloroform extraction followed by column purification (Zymo Research, R1013) as described
above. 1/3 lysate volume was kept as input before layering onto the sucrose gradient and RNA
was extracted from the input lysate by Trizol extraction followed by column purification. 1.5 ¬µg
RNA in 5.5 ¬µL was mixed with 0.5 ¬µL 2uM RT_Nluc26_UMI12_Read1Partial (Table S6) and 0.5
¬µL 10 mM dNTPs each. The RNA samples were then denatured at 65¬∞C for 5 min and chilled to
4¬∞C. 3.5 ¬µL reverse transcription mix was added to 10 ¬µL total reaction volume: 2 ¬µL 5x
Superscript IV buffer, 0.5 ¬µL 10 mM DTT, 0.5 ¬µL Superase-In (ThermoFisher Scientific,
AM2694), 0.5 ¬µL Superscript IV (Thermo 18091050). The reaction was incubated at 55¬∞C for 45
min and inactivated at 80¬∞C for 10 min. Variant 5‚Äô UTR amplicon was amplified from the reverse
transcription reaction via PCR under the following reaction conditions: 4 ¬µL RT reaction, 40 ¬µL
2x Q5 Hot Start Master Mix (NEB M0494S), 0.8 ¬µL 100x SYBR (Thermo S7563), 4 ¬µL 10 ¬µM
T7_28_HBB_29_F, 4 ¬µL 10 ¬µM Nanoluc_ORF_R, in 80 ¬µL total reaction volume. Cycling
conditions were as follows: 98¬∞C for 60 sec, and 15 cycles of 98¬∞C for 10 sec, 68¬∞C for 10 sec,
72¬∞C for 10 sec. PCR product was purified on silica columns (NEB T1034) and assembly with
Nluc_HBB_3UTR fragment was performed as described above for initial preparation of IVT
template using HBB29_N35 amplicon. The mRNA was in vitro transcribed, capped and
polyadenylated as described above. The same process of transfection, fractionation, reverse
transcription, PCR amplification, assembly and in vitro transcription was repeated.
For sequencing library preparation the RT reaction was PCR amplified under the
following conditions: 1 ¬µL RT reaction, 10 ¬µL 2x Q5 Hot Start Master Mix (NEB M0494S), 0.2 ¬µL
100x SYBR (Thermo S7563), 1 ¬µL 10 ¬µM Read1, 1 ¬µL 10 ¬µM Read2Partial_HBB29 in 20 ¬µL
total reaction volume. Cycling conditions were as follows: 98¬∞C for 60 sec, and 15 cycles of
98¬∞C for 10 sec, 68¬∞C for 10 sec, 72¬∞C for 10 sec. Sequencing adaptors were added using the
following conditions for final round PCR: 1 ¬µL first round PCR reaction, 10 ¬µL 2x Q5 Hot Start
Master Mix, 0.2 ¬µL 100x SYBR, 1 ¬µL 10uM NEBNext Index Primer (NEB E7335, NEB E7500,
NEB E7710, NEB E7730, NEB E6609), 1¬µL 10uM NEBNext Universal PCR Primer in 20 ¬µL
total volume. Cycling conditions are: 98¬∞C for 60 sec, and 5 cycles of 98¬∞C for 10 sec, 72¬∞C for
10 sec. All barcoded samples were then pooled at equal volumes and purified with 1.1x
SPRIselect beads Beckman Coulter B23317). Sequencing was performed at the Stanford
Functional Genomics Facility (SFGF) at Stanford University, on the Illumina NextSeq 550
instrument, using a high output kit, 1x81 cycles. Primer sequences and the sequencing
construct layout are provided in Table S6.

62

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

Polysome selection library sequencing data analysis
Following adapter trimming, 670440 sequences with at least 10 summed read count across all
libraries combined were set as the reference. Each library was aligned to this indexed reference
using Bowtie289. Only uniquely mapping reads with edit distance ‚â§3 were retained. Alignments
were further deduplicated using UMIcollapse (-p 0.05, -k 1)90. This results in the matrix of read
count where rows are different sequence variants and columns are the samples.
Normalized counts were obtained by dividing the matrix column-wise by total read
counts per sample. For sequence variants with at least 15 reads in any one of the samples, a
regression model was fitted on normalized read counts with the sequential selection rounds as
ordinal predictors, penalizing differences between coefficients of adjacent groups (R package
ordPens)

97

. False discovery rate was estimated by Benjamini-Hochberg procedure. For

choosing the final set of candidates, the criteria of ‚â•15 read counts in the final round polysome
selection library and ‚â•2 fold enrichment over input in the final round was also required.
For analysis of k-mers, 1 million reads (prior to alignment and analysis for highly
enriched individual sequences) were sampled from each library. Position-specific k-mers were
counted and statistical significance of pair-wise enrichments for each position-specific k-mers
are calculated using kpLogo85. The parameters were: zero-order Markov model background;
2‚â§k‚â§6; -shift 0 and -max-shift 0; binomial test with Bonferroni correction.
Design algorithms/analysis
The protein sequences for each target were used to generate DNA sequences at Integrated
DNA

Technologies

(IDT,

https://www.idtdna.com/CodonOpt),

(https://ecommerce.twistdna.com/app),

and

Twist

Biosciences
GENEWIZ

(https://clims4.genewiz.com/Toolbox/CodonOptimization). Solutions from LinearDesign were
obtained using the LinearDesign server (http://rna.baidu.com/). Ribotree solutions were
terminated after 6000 iterations. The RiboTree code is available for noncommercial use at
https://eternagame.org/about/software, with example usage to replicate runs for this work
provided.
Structure prediction and ensemble-based calculations were performed using LinearFold
and LinearPartition with ViennaRNA, CONTRAfold, and EternaFold parameters. Secondary
structure features were calculated from predicted MFE structures using RiboGraphViz
(www.github.com/DasLab/RiboGraphViz). CAI (Codon Adaptation Index) was calculated as the

63

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

geometric mean of the relative usage frequency of codons along the length of the coding region,
as previously described45:
ùêø

ùêø‚àí1

ùê∂ùê¥ùêº = ( ‚àè ùë§ùëñ)
ùëñ=2

; ùë§ùëñ = ùëìùëñ/ùëöùëéùë•(ùëìùëó),

Where fj represents the frequency of all codons coding for amino acid at position i. Scripts to
reproduce degradation and structure predictions are available in the ‚ÄúOpenVaccine-solves‚Äù
database under an Open COVID license at https://eternagame.org/about/software.
Quantification and Statistical Procedures
In all figures, data are presented as mean, SD or SEM as stated in the figure legends, and *p ‚â§
0.05 is considered significant (ns: p > 0.05; *p ‚â§ 0.05; **p ‚â§ 0.01; ***p ‚â§ 0.001; ****p ‚â§ 0.0001).
Blinding and randomization were not used in any of the experiments. Number of independent
biological replicates used for the experiments are listed in the figure legends. Tests, two-tailed
unpaired Student‚Äôs t-test if not stated otherwise, and specific p-values used are indicated in the
figure legends. In all cases, multiple independent experiments were performed on different days
to verify the reproducibility of experimental findings. Errors for in-cell degradation coefficients
are standard errors of coefficient estimates. Errors for in-cell ribosome load are estimated by
bootstrapping where fraction labels are shuffled and before scaling by spike-in normalization
factors. Errors for predicted expression values are estimated by Taylor series method. Error and
significance tests for fitting single-exponential in-solution half-lives were estimated by
non-parametric bootstrapping.

ACCESSION NUMBERS
RNA sequencing data from RNA-seq experiments are being deposited in the Gene Expression
Omnibus (GEO). Single-nucleotide-resolution in-line probing and SHAPE data are deposited at
the following RNA Mapping Database 98 (http://rmdb.stanford.edu) accession numbers:
In-line-seq datasets:
RYOS1_NMD_0000 (no modification)
RYOS1_MGPH_0000 ([Mg2+] = 10 mM, pH = 10, 24ÀöC, 1 day)
RYOS1_PH10_0000 ([Mg2+] = 0 mM, pH = 10, 24ÀöC, 7 days)
RYOS1_MG50_0000 ([Mg2+] = 10 mM, pH = 7.2, 50ÀöC, 1 day)
RYOS1_50C_0000 ([Mg2+] = 0 mM, pH = 7.2, 50ÀöC, 7 days)
SHAPE_RYOS_0620 (SHAPE 1M7 reactivity)
64

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

One-by-one follow ups
RYOSFL_MOD_0001
RYOSFL_MOD_0002
RYOSFL_MOD_0003
RYOSFL_MOD_0004
RYOSFL_MOD_0005
RYOSFL_MOD_0006
RYOSFL_MOD_0007
RYOSFL_MOD_0008

SUPPLEMENTAL INFORMATION
Supplemental Information includes 7 Supplemental Figures and 7 Supplemental Tables.

DECLARATION OF INTEREST
Stanford University has submitted provisional patent applications related to use of the Hoxa9 P4
stem-loop and the CoV2 5‚Äô UTR, computational design of mRNAs, chemically modified
nucleotides to stabilize RNA therapeutics, and PERSIST-seq.

SUPPLEMENTAL TABLES

Table S1. Attributes for pooled 233 sequences, including nucleotide sequences, sequence
annotation, ribosome load, in-solution RNA degradation half-lives, in-cell RNA degradation
half-lives, predicted protein expression, and biophysical properties. ‚ÄúNA‚Äù indicates values not
measured or calculated for select constructs.
Table S2. Attributes for CoV-2 5‚Äô UTR mutagenesis sequences
Table S3. Frequency and statistics of position-specific k-mers after polysome selection.
Table S4. Normalized DMS and SHAPE (1M7) data on P4-P6, Yellowstone and LinearDesign-1
sequences.
Table S5. Attributes for 24 CDS designs, including designer/source, nucleotide sequences,
in-solution half-lives, luciferase expression values, biophysical properties, and predicted
structural metrics.
Table S6. List of primers and construct layouts.
Table S7. Eterna OpenVaccine participants List of primers and construct layouts
Table S8. List of OpenVaccine donors.

65

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

REFERENCES
1.

Kowalski, P. S., Rudra, A., Miao, L. & Anderson, D. G. Delivering the Messenger: Advances
in Technologies for Therapeutic mRNA Delivery. Mol. Ther. 27, 710‚Äì728 (2019).

2.

Pardi, N., Hogan, M. J., Porter, F. W. & Weissman, D. mRNA vaccines - a new era in
vaccinology. Nat. Rev. Drug Discov. 17, 261‚Äì279 (2018).

3.

Sahin, U., Karik√≥, K. & T√ºreci, √ñ. mRNA-based therapeutics--developing a new class of
drugs. Nat. Rev. Drug Discov. 13, 759‚Äì780 (2014).

4.

Jackson, N. A. C., Kester, K. E., Casimiro, D., Gurunathan, S. & DeRosa, F. The promise of
mRNA vaccines: a biotech and industrial perspective. npj Vaccines 5, 11 (2020).

5.

Weng, Y. et al. The challenge and prospect of mRNA therapeutics landscape. Biotechnol.
Adv. 40, 107534 (2020).

6.

Crommelin, D. J. A., Anchordoquy, T. J., Volkin, D. B., Jiskoot, W. & Mastrobattista, E.
Addressing the Cold Reality of mRNA Vaccine Stability. J. Pharm. Sci. 110, 997‚Äì1001
(2021).

7.

Wayment-Steele, H. K. et al. Theoretical basis for stabilizing messenger RNA through
secondary structure design. BioRxiv (2020) doi:10.1101/2020.08.22.262931.

8.

Mauger, D. M. et al. mRNA structure regulates protein expression through changes in
functional half-life. Proc Natl Acad Sci USA 116, 24075‚Äì24083 (2019).

9.

Thess, A. et al. Sequence-engineered mRNA Without Chemical Nucleoside Modifications
Enables an Effective Protein Therapy in Large Animals. Mol. Ther. 23, 1456‚Äì1464 (2015).

10. Lee, J. et al. RNA design rules from a massive open laboratory. Proc Natl Acad Sci USA
111, 2122‚Äì2127 (2014).
11. Jia, L. et al. Decoding mRNA translatability and stability from the 5‚Äô UTR. Nat. Struct. Mol.
Biol. 27, 814‚Äì821 (2020).
12. Asrani, K. H. et al. Optimization of mRNA untranslated regions for improved expression of
66

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

therapeutic mRNA. RNA Biol. 15, 756‚Äì762 (2018).
13. Sultana, N. et al. Optimization of 5‚Äô Untranslated Region of Modified mRNA for Use in
Cardiac or Hepatic Ischemic Injury. Mol. Ther. Methods Clin. Dev. 17, 622‚Äì633 (2020).
14. Leppek, K., Das, R. & Barna, M. Functional 5‚Äô UTR mRNA structures in eukaryotic
translation regulation and how to find them. Nat. Rev. Mol. Cell Biol. 19, 158‚Äì174 (2018).
15. Sample, P. J. et al. Human 5‚Äô UTR design and variant effect prediction from a massively
parallel translation assay. Nat. Biotechnol. 37, 803‚Äì809 (2019).
16. Cao, J. et al. High-Throughput 5‚Ä≤ UTR Engineering for Enhanced Protein Production in
Non-Viral Gene Therapies. BioRxiv (2020) doi:10.1101/2020.03.24.006486.
17. Zhao, W. et al. Massively parallel functional annotation of 3‚Äô untranslated regions. Nat.
Biotechnol. 32, 387‚Äì391 (2014).
18. Orlandini von Niessen, A. G. et al. Improving mRNA-Based Therapeutic Gene Delivery by
Expression-Augmenting 3‚Äô UTRs Identified by Cellular Library Screening. Mol. Ther. 27,
824‚Äì836 (2019).
19. Schwanh√§usser, B. et al. Global quantification of mammalian gene expression control.
Nature 473, 337‚Äì342 (2011).
20. Hsieh, A. C. et al. The translational landscape of mTOR signalling steers cancer initiation
and metastasis. Nature 485, 55‚Äì61 (2012).
21. Thoreen, C. C. et al. A unifying model for mTORC1-mediated regulation of mRNA
translation. Nature 485, 109‚Äì113 (2012).
22. Leppek, K. et al. Gene- and Species-Specific Hox mRNA Translation by Ribosome
Expansion Segments. Mol. Cell 80, 980-995.e13 (2020).
23. Patel, M., Siegel, A. J. & Berry, J. O. Untranslated regions of FbRbcS1 mRNA mediate
bundle sheath cell-specific gene expression in leaves of a C4 plant. J. Biol. Chem. 281,
25485‚Äì25491 (2006).
24. Wilusz, J. E. et al. A triple helix stabilizes the 3‚Äô ends of long noncoding RNAs that lack
67

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

poly(A) tails. Genes Dev. 26, 2392‚Äì2407 (2012).
25. Hickey, K. L. et al. GIGYF2 and 4EHP Inhibit Translation Initiation of Defective Messenger
RNAs to Assist Ribosome-Associated Quality Control. Mol. Cell 79, 950-962.e6 (2020).
26. Wollner, C. J. et al. A mRNA-LNP vaccine against Dengue Virus elicits robust,
serotype-specific immunity. BioRxiv (2021) doi:10.1101/2021.01.05.425517.
27. Ferizi, M. et al. Human cellular CYBA UTR sequences increase mRNA translation without
affecting the half-life of recombinant RNA transcripts. Sci. Rep. 6, 39149 (2016).
28. Zeng, C. et al. Leveraging mRNAs sequences to express SARS-CoV-2 antigens in vivo.
BioRxiv (2020) doi:10.1101/2020.04.01.019877.
29. Kim, D. et al. The Architecture of SARS-CoV-2 Transcriptome. Cell 181, 914-921.e10
(2020).
30. Huston, N. C. et al. Comprehensive in vivo secondary structure of the SARS-CoV-2
genome reveals novel regulatory motifs and mechanisms. Mol. Cell 81, 584-598.e5 (2021).
31. Chiu, W.-W., Kinney, R. M. & Dreher, T. W. Control of translation by the 5‚Äô- and 3‚Äô-terminal
regions of the dengue virus genome. J. Virol. 79, 8303‚Äì8315 (2005).
32. Holden, K. L. & Harris, E. Enhancement of dengue virus translation: role of the 3‚Äô
untranslated region and the terminal 3‚Äô stem-loop domain. Virology 329, 119‚Äì133 (2004).
33. Simon, A. E. & Miller, W. A. 3‚Äô cap-independent translation enhancers of plant viruses.
Annu. Rev. Microbiol. 67, 21‚Äì42 (2013).
34. Nicholson, B. L. & White, K. A. 3‚Äô Cap-independent translation enhancers of positive-strand
RNA plant viruses. Curr. Opin. Virol. 1, 373‚Äì380 (2011).
35. Gallie, D. R. The 5‚Äô-leader of tobacco mosaic virus promotes translation through enhanced
recruitment of eIF4F. Nucleic Acids Res. 30, 3401‚Äì3411 (2002).
36. Gallie, D. R., Tanguay, R. L. & Leathers, V. The tobacco etch viral 5‚Ä≤ leader and poly(A) tail
are functionally synergistic regulators of translation. Gene 165, 233‚Äì238 (1995).
37. Shirokikh, N. E. & Spirin, A. S. Poly(A) leader of eukaryotic mRNA bypasses the
68

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

dependence of translation on initiation factors. Proc Natl Acad Sci USA 105, 10738‚Äì10743
(2008).
38. Sokoloski, K. J. et al. Sindbis virus usurps the cellular HuR protein to stabilize its transcripts
and promote productive infections in mammalian and mosquito cells. Cell Host Microbe 8,
196‚Äì207 (2010).
39. Palusa, S., Ndaluka, C., Bowen, R. A., Wilusz, C. J. & Wilusz, J. The 3‚Äô untranslated region
of the rabies virus glycoprotein mRNA specifically interacts with cellular PCBP2 protein and
promotes transcript stability. PLoS ONE 7, e33561 (2012).
40. Garneau, N. L. et al. The 3‚Äô untranslated region of sindbis virus represses deadenylation of
viral transcripts in mosquito and Mammalian cells. J. Virol. 82, 880‚Äì892 (2008).
41. Kozak, M. Features in the 5‚Äô non-coding sequences of rabbit alpha and beta-globin mRNAs
that affect translational efficiency. J. Mol. Biol. 235, 95‚Äì110 (1994).
42. Babendure, J. R., Babendure, J. L., Ding, J.-H. & Tsien, R. Y. Control of mammalian
translation by mRNA structure near caps. RNA 12, 851‚Äì861 (2006).
43. Osuna, B. A., Howard, C. J., Kc, S., Frost, A. & Weinberg, D. E. In vitro analysis of RQC
activities provides insights into the mechanism and function of CAT tailing. elife 6, (2017).
44. England, C. G., Ehlerding, E. B. & Cai, W. Nanoluc: A small luciferase is brightening up the
field of bioluminescence. Bioconjug. Chem. 27, 1175‚Äì1187 (2016).
45. Sharp, P. M. & Li, W. H. The codon Adaptation Index--a measure of directional synonymous
codon usage bias, and its potential applications. Nucleic Acids Res. 15, 1281‚Äì1295 (1987).
46. Zhang, H. et al. LinearDesign: Efficient Algorithms for Optimized mRNA Sequence Design.
arXiv (2020).
47. Ding, Y. et al. In vivo genome-wide profiling of RNA secondary structure reveals novel
regulatory features. Nature 505, 696‚Äì700 (2014).
48. Shah, P., Ding, Y., Niemczyk, M., Kudla, G. & Plotkin, J. B. Rate-limiting steps in yeast
protein translation. Cell 153, 1589‚Äì1601 (2013).
69

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

49. Tuller, T. & Zur, H. Multiple roles of the coding sequence 5‚Äô end in gene expression
regulation. Nucleic Acids Res. 43, 13‚Äì28 (2015).
50. Manfredonia, I. & Incarnato, D. Structure and regulation of coronavirus genomes:
state-of-the-art and novel insights from SARS-CoV-2 studies. Biochem. Soc. Trans. 49,
341‚Äì352 (2021).
51. Manfredonia, I. et al. Genome-wide mapping of SARS-CoV-2 RNA structures identifies
therapeutically-relevant elements. Nucleic Acids Res. 48, 12436‚Äì12452 (2020).
52. Lan, T. C. T. et al. Structure of the full SARS-CoV-2 RNA genome in infected cells. BioRxiv
(2020) doi:10.1101/2020.06.29.178343.
53. Garneau, N. L., Wilusz, J. & Wilusz, C. J. The highways and byways of mRNA decay. Nat.
Rev. Mol. Cell Biol. 8, 113‚Äì126 (2007).
54. Mayr, C. What are 3‚Äô utrs doing? Cold Spring Harb. Perspect. Biol. 11, (2019).
55. Matoulkova, E., Michalova, E., Vojtesek, B. & Hrstka, R. The role of the 3‚Äô untranslated
region in post-transcriptional regulation of protein expression in mammalian cells. RNA Biol.
9, 563‚Äì576 (2012).
56. Mayya, V. K. & Duchaine, T. F. Ciphers and Executioners: How 3‚Äô-Untranslated Regions
Determine the Fate of Messenger RNAs. Front. Genet. 10, 6 (2019).
57. Leonhardt, C. et al. Single-cell mRNA transfection studies: delivery, kinetics and statistics
by numbers. Nanomedicine 10, 679‚Äì688 (2014).
58. Wang, H. et al. Diversity of putative archaeal RNA viruses in metagenomic datasets of a
yellowstone acidic hot spring. Springerplus 4, 189 (2015).
59. Siegfried, N. A., Busan, S., Rice, G. M., Nelson, J. A. E. & Weeks, K. M. RNA motif
discovery by SHAPE and mutational profiling (SHAPE-MaP). Nat. Methods 11, 959‚Äì965
(2014).
60. Zubradt, M. et al. DMS-MaPseq for genome-wide or targeted RNA structure probing in vivo.
Nat. Methods 14, 75‚Äì82 (2017).
70

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

61. Kaukinen, U., Lyytik√§inen, S., Mikkola, S. & L√∂nnberg, H. The reactivity of phosphodiester
bonds within linear single-stranded oligoribonucleotides is strongly dependent on the base
sequence. Nucleic Acids Res. 30, 468‚Äì474 (2002).
62. Mikkola, S., Kaukinen, U. & L√∂nnberg, H. The effect of secondary structure on cleavage of
the phosphodiester bonds of RNA. Cell Biochem. Biophys. 34, 95‚Äì119 (2001).
63. Li, Y. & Breaker, R. R. Kinetics of RNA Degradation by Specific Base Catalysis of
Transesterification Involving the 2‚Äò-Hydroxyl Group. J. Am. Chem. Soc. 121, 5364‚Äì5372
(1999).
64. Seetin, M. G., Kladwang, W., Bida, J. P. & Das, R. Massively parallel RNA chemical
mapping with a reduced bias MAP-seq protocol. Methods Mol. Biol. 1086, 95‚Äì117 (2014).
65. Regulski, E. E. & Breaker, R. R. In-line probing analysis of riboswitches. Methods Mol. Biol.
419, 53‚Äì67 (2008).
66. Lorenz, R. et al. ViennaRNA Package 2.0. Algorithms Mol. Biol. 6, 26 (2011).
67. Karik√≥, K. et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic
vector with increased translational capacity and biological stability. Mol. Ther. 16,
1833‚Äì1840 (2008).
68. Karik√≥, K., Buckstein, M., Ni, H. & Weissman, D. Suppression of RNA recognition by
Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA.
Immunity 23, 165‚Äì175 (2005).
69. Hornung, V. et al. 5‚Äô-Triphosphate RNA is the ligand for RIG-I. Science 314, 994‚Äì997
(2006).
70. Anderson, B. R. et al. Incorporation of pseudouridine into mRNA enhances translation by
diminishing PKR activation. Nucleic Acids Res. 38, 5884‚Äì5892 (2010).
71. Nallagatla, S. R. & Bevilacqua, P. C. Nucleoside modifications modulate activation of the
protein kinase PKR in an RNA structure-specific manner. RNA 14, 1201‚Äì1213 (2008).
72. Davis, D. R. Stabilization of RNA stacking by pseudouridine. Nucleic Acids Res. 23,
71

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

5020‚Äì5026 (1995).
73. Yoffe, A. M. et al. Predicting the sizes of large RNA molecules. Proc Natl Acad Sci USA
105, 16153‚Äì16158 (2008).
74. Polack, F. P. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl.
J. Med. 383, 2603‚Äì2615 (2020).
75. Baden, L. R. et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J.
Med. 384, 403‚Äì416 (2021).
76. Hu, B., Guo, H., Zhou, P. & Shi, Z.-L. Characteristics of SARS-CoV-2 and COVID-19. Nat.
Rev. Microbiol. 19, 141‚Äì154 (2020).
77. Corbett, K. S. et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen
preparedness. Nature 586, 567‚Äì571 (2020).
78. Juszkiewicz, S. et al. Ribosome collisions trigger cis-acting feedback inhibition of translation
initiation. elife 9, (2020).
79. Wu, C. C.-C., Peterson, A., Zinshteyn, B., Regot, S. & Green, R. Ribosome collisions
trigger general stress responses to regulate cell fate. Cell 182, 404-416.e14 (2020).
80. Zhang, L. Multi-epitope vaccines: a promising strategy against tumors and viral infections.
Cell. Mol. Immunol. 15, 182‚Äì184 (2018).
81. Sahin, U. et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic
immunity against cancer. Nature 547, 222‚Äì226 (2017).
82. Mie, M., Shimizu, S., Takahashi, F. & Kobatake, E. Selection of mRNA 5‚Äô-untranslated
region sequence with high translation efficiency through ribosome display. Biochem.
Biophys. Res. Commun. 373, 48‚Äì52 (2008).
83. Kozak, M. An analysis of 5‚Äô-noncoding sequences from 699 vertebrate messenger RNAs.
Nucleic Acids Res. 15, 8125‚Äì8148 (1987).
84. Kozak, M. The scanning model for translation: an update. J. Cell Biol. 108, 229‚Äì241 (1989).
85. Wu, X. & Bartel, D. P. kpLogo: positional k-mer analysis reveals hidden specificity in
72

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

biological sequences. Nucleic Acids Res. 45, W534‚ÄìW538 (2017).
86. Eisenhut, P. et al. Systematic use of synthetic 5‚Äô-UTR RNA structures to tune protein
translation improves yield and quality of complex proteins in mammalian cell factories.
Nucleic Acids Res. 48, e119 (2020).
87. Xue, S. et al. RNA regulons in Hox 5‚Äô UTRs confer ribosome specificity to gene regulation.
Nature 517, 33‚Äì38 (2015).
88. Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads.
EMBnet j. 17, 10 (2011).
89. Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat. Methods
9, 357‚Äì359 (2012).
90. Liu, D. Algorithms for efficiently collapsing reads with Unique Molecular Identifiers. PeerJ 7,
e8275 (2019).
91. Hall, M. P. et al. Engineered luciferase reporter from a deep sea shrimp utilizing a novel
imidazopyrazinone substrate. ACS Chem. Biol. 7, 1848‚Äì1857 (2012).
92. Incarnato, D., Morandi, E., Simon, L. M. & Oliviero, S. RNA Framework: an all-in-one toolkit
for the analysis of RNA structures and post-transcriptional modifications. Nucleic Acids
Res. 46, e97 (2018).
93. Reuter, J. S. & Mathews, D. H. RNAstructure: software for RNA secondary structure
prediction and analysis. BMC Bioinformatics 11, 129 (2010).
94. Kladwang, W. et al. Standardization of RNA chemical mapping experiments. Biochemistry
53, 3063‚Äì3065 (2014).
95. Cheng, C. Y. et al. Consistent global structures of complex RNA states through
multidimensional chemical mapping. elife 4, e07600 (2015).
96. Kim, H., Cordero, P., Das, R. & Yoon, S. HiTRACE-Web: an online tool for robust analysis
of high-throughput capillary electrophoresis. Nucleic Acids Res. 41, W492-8 (2013).
97. Gertheiss, J. & Tutz, G. Penalized Regression with Ordinal Predictors. Int. Statistical Rev.
73

bioRxiv preprint doi: https://doi.org/10.1101/2021.03.29.437587; this version posted March 30, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made
available under aCC-BY-NC 4.0 International license.

77, 345‚Äì365 (2009).
98. Yesselman, J. D. et al. Updates to the RNA mapping database (RMDB), version 2. Nucleic
Acids Res. 46, D375‚ÄìD379 (2018).

74

